

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Mitochondrial apoptosis and BH3 mimetics | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/5-2804/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/5-2804" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Mitochondrial apoptosis and BH3 mimetics" />
    
            <meta name="og:title" content="F1000Research Article: Mitochondrial apoptosis and BH3 mimetics.">
            <meta name="og:description" content="Read the latest article version by Haiming Dai, X. Wei Meng, Scott H. Kaufmann, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="10375">
            <meta name="article-id" content="9629">
            <meta name="dc.title" content="Mitochondrial apoptosis and BH3 mimetics">
            <meta name="dc.description" content="The BCL2-selective BH3 mimetic venetoclax was recently approved for the treatment of relapsed, chromosome 17p-deleted chronic lymphocytic leukemia (CLL) and is undergoing extensive testing, alone and in combination, in lymphomas, acute leukemias, and solid tumors. Here we summarize recent advances in understanding of the biology of BCL2 family members that shed light on the action of BH3 mimetics, review preclinical and clinical studies leading to the regulatory approval of venetoclax, and discuss future investigation of this new class of antineoplastic agent.">
            <meta name="dc.subject" content="BCL-2 inhibitors, venetoclax, BAX activation, BAK activation, BH3 mimetics">
            <meta name="dc.creator" content="Dai, Haiming">
            <meta name="dc.creator" content="Meng, X. Wei">
            <meta name="dc.creator" content="Kaufmann, Scott H.">
            <meta name="dc.date" content="2016/12/01">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.9629.1">
            <meta name="dc.source" content="F1000Research 2016 5:2804">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="BCL-2 inhibitors">
            <meta name="prism.keyword" content="venetoclax">
            <meta name="prism.keyword" content="BAX activation">
            <meta name="prism.keyword" content="BAK activation">
            <meta name="prism.keyword" content="BH3 mimetics">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2016/12/01">
            <meta name="prism.volume" content="5">
            <meta name="prism.number" content="2804">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.9629.1">
            <meta name="prism.url" content="https://f1000research.com/articles/5-2804">
            <meta name="citation_title" content="Mitochondrial apoptosis and BH3 mimetics">
            <meta name="citation_abstract" content="The BCL2-selective BH3 mimetic venetoclax was recently approved for the treatment of relapsed, chromosome 17p-deleted chronic lymphocytic leukemia (CLL) and is undergoing extensive testing, alone and in combination, in lymphomas, acute leukemias, and solid tumors. Here we summarize recent advances in understanding of the biology of BCL2 family members that shed light on the action of BH3 mimetics, review preclinical and clinical studies leading to the regulatory approval of venetoclax, and discuss future investigation of this new class of antineoplastic agent.">
            <meta name="citation_description" content="The BCL2-selective BH3 mimetic venetoclax was recently approved for the treatment of relapsed, chromosome 17p-deleted chronic lymphocytic leukemia (CLL) and is undergoing extensive testing, alone and in combination, in lymphomas, acute leukemias, and solid tumors. Here we summarize recent advances in understanding of the biology of BCL2 family members that shed light on the action of BH3 mimetics, review preclinical and clinical studies leading to the regulatory approval of venetoclax, and discuss future investigation of this new class of antineoplastic agent.">
            <meta name="citation_keywords" content="BCL-2 inhibitors, venetoclax, BAX activation, BAK activation, BH3 mimetics">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Haiming Dai">
            <meta name="citation_author_institution" content="Division of Oncology Research , Mayo Clinic, Rochester, MN, 55905, USA">
            <meta name="citation_author_institution" content="Center for Medical Physics and Technology, Hefei Institute of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China">
            <meta name="citation_author_institution" content="Department of Molecular Pharmacology &amp; Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA">
            <meta name="citation_author" content="X. Wei Meng">
            <meta name="citation_author_institution" content="Division of Oncology Research , Mayo Clinic, Rochester, MN, 55905, USA">
            <meta name="citation_author_institution" content="Department of Molecular Pharmacology &amp; Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA">
            <meta name="citation_author" content="Scott H. Kaufmann">
            <meta name="citation_author_institution" content="Division of Oncology Research , Mayo Clinic, Rochester, MN, 55905, USA">
            <meta name="citation_author_institution" content="Department of Molecular Pharmacology &amp; Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA">
            <meta name="citation_publication_date" content="2016/12/01">
            <meta name="citation_volume" content="5">
            <meta name="citation_publication_number" content="2804">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.9629.1">
            <meta name="citation_firstpage" content="2804">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/5-2804/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/5-2804.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=10375 /> <input type=hidden id=articleId name=articleId value=9629 /> <input type=hidden id=xmlUrl value="/articles/5-2804/v1/xml"/> <input type=hidden id=xmlFileName value="-5-2804-v1.xml"> <input type=hidden id=article_uuid value=bdd0363f-6d1e-467e-85a9-b9f68b3f55ab /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Mitochondrial apoptosis and BH3 mimetics"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.9629.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.9629.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/5-2804"
  },
  "headline": "Mitochondrial apoptosis and BH3 mimetics",
  "datePublished": "2016-12-01T10:12:50",
  "dateModified": "2016-12-01T10:12:50",
  "author": [
    {
      "@type": "Person",
      "name": "Haiming Dai"
    },    {
      "@type": "Person",
      "name": "X. Wei Meng"
    },    {
      "@type": "Person",
      "name": "Scott H. Kaufmann"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The BCL2-selective BH3 mimetic venetoclax was recently approved for the treatment of relapsed, chromosome 17p-deleted chronic lymphocytic leukemia (CLL) and is undergoing extensive testing, alone and in combination, in lymphomas, acute leukemias, and solid tumors. Here we summarize recent advances in understanding of the biology of BCL2 family members that shed light on the action of BH3 mimetics, review preclinical and clinical studies leading to the regulatory approval of venetoclax, and discuss future investigation of this new class of antineoplastic agent."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/5-2804.html",
            "name": "Mitochondrial apoptosis and BH3 mimetics"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Mitochondrial apoptosis and BH3 mimetics </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=10375 data-id=9629 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9629.1" data-recommended="" data-doi="10.12688/f1000research.9629.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/5-2804/v1/pdf?article_uuid=bdd0363f-6d1e-467e-85a9-b9f68b3f55ab" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-9629-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-9629-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-9629-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Dai H, Meng XW and Kaufmann SH. Mitochondrial apoptosis and BH3 mimetics [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2804 (<a class=new-orange href="https://doi.org/10.12688/f1000research.9629.1" target=_blank>https://doi.org/10.12688/f1000research.9629.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-9629-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=9629 id=track-article-signin-9629 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9629?target=/articles/5-2804.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10375 /> <input name=articleId type=hidden value=9629 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Mitochondrial apoptosis and BH3 mimetics</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:Dai.Haiming@Mayo.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Haiming Dai</span></a><sup>1-3</sup><sup>*</sup>,&nbsp;</span><span class=""><a href="mailto:Meng.Xuewei@Mayo.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>X. Wei Meng</span></a><sup>1,2</sup><sup>*</sup>,&nbsp;</span><span class=""><a href="mailto:Kaufmann.Scott@Mayo.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Scott H. Kaufmann</span></a><a href="https://orcid.org/0000-0002-4900-7145" target=_blank id=author-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-4900-7145</div><sup>1,2</sup><sup>*</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:Dai.Haiming@Mayo.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Haiming Dai</span></a><sup>1-3</sup><sup>*</sup>,&nbsp;</span><span class=""><a href="mailto:Meng.Xuewei@Mayo.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>X. Wei Meng</span></a><sup>1,2</sup><sup>*</sup>,&nbsp;</span><span class=""><a href="mailto:Kaufmann.Scott@Mayo.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Scott H. Kaufmann</span></a><a href="http://orcid.org/0000-0002-4900-7145" target=_blank id=mauthor-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-4900-7145</div><sup>1,2</sup><sup>*</sup></span></div> </div> <div class="authors extra-info"> <sup>*</sup> Equal contributors </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 01 Dec 2016 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.9629.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Division of Oncology Research , Mayo Clinic, Rochester, MN, 55905, USA<br/> <sup>2</sup> Department of Molecular Pharmacology &amp; Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA<br/> <sup>3</sup> Center for Medical Physics and Technology, Hefei Institute of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=18257-17747></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=18259-17748></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=18258-17749></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The BCL2-selective BH3 mimetic venetoclax was recently approved for the treatment of relapsed, chromosome 17p-deleted chronic lymphocytic leukemia (CLL) and is undergoing extensive testing, alone and in combination, in lymphomas, acute leukemias, and solid tumors. Here we summarize recent advances in understanding of the biology of BCL2 family members that shed light on the action of BH3 mimetics, review preclinical and clinical studies leading to the regulatory approval of venetoclax, and discuss future investigation of this new class of antineoplastic agent. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> BCL-2 inhibitors, venetoclax, BAX activation, BAK activation, BH3 mimetics </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Haiming Dai (<a href="mailto:Dai.Haiming@Mayo.edu">Dai.Haiming@Mayo.edu</a>) <br> X. Wei Meng (<a href="mailto:Meng.Xuewei@Mayo.edu">Meng.Xuewei@Mayo.edu</a>) <br> Scott H. Kaufmann (<a href="mailto:Kaufmann.Scott@Mayo.edu">Kaufmann.Scott@Mayo.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Haiming Dai, X. Wei Meng, Scott H. Kaufmann </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> Preparation of this review was supported in part by a grant from the NIH (R01 CA166741). Haiming Dai is also supported by the Hundred-Talent Program of the Chinese Academy of Sciences. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2016 Dai H <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Dai H, Meng XW and Kaufmann SH. Mitochondrial apoptosis and BH3 mimetics [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2804 (<a href="https://doi.org/10.12688/f1000research.9629.1" target=_blank>https://doi.org/10.12688/f1000research.9629.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 01 Dec 2016, <b>5</b>(F1000 Faculty Rev):2804 (<a href="https://doi.org/10.12688/f1000research.9629.1" target=_blank>https://doi.org/10.12688/f1000research.9629.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 01 Dec 2016, <b>5</b>(F1000 Faculty Rev):2804 (<a href="https://doi.org/10.12688/f1000research.9629.1" target=_blank>https://doi.org/10.12688/f1000research.9629.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d41976e235>Introduction</h2><p class="" id=d41976e238>The recent regulatory approval of venetoclax for the treatment of chronic lymphocytic leukemia (CLL) culminates 30 years of investigation in many labs worldwide. Milestones in this effort have included the cloning of <i>BCL2</i> at the t(14;18) translocation in follicular lymphomas<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>, demonstration that BCL2 inhibits cell death<sup><a href="#ref-3">3</a>,<a href="#ref-4">4</a></sup>, realization that BCL2 is elevated in CLL<sup><a href="#ref-5">5</a>,<a href="#ref-6">6</a></sup>, recognition that BCL2 and its anti-apoptotic paralogs bind BH3-only proteins through their BH3-binding grooves<sup><a href="#ref-7">7</a></sup>, identification of ABT-737 and navitoclax as BH3-binding groove-directed inhibitors of BCL2 and BCLX<sub>L</sub><sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>, demonstration that navitoclax is active against CLL<sup><a href="#ref-10">10</a></sup>, and derivation of venetoclax as a BCL2-selective BH3 mimetic<sup><a href="#ref-11">11</a></sup>. While the approval of venetoclax for CLL is a triumph in its own right, the challenge remains to optimize the use of this agent and other BH3 mimetics for improved therapy of diverse malignancies. To provide context for these ongoing efforts, we review recent progress in understanding the action of BCL2 family proteins, summarize the clinical status of venetoclax and other BH3 mimetics, and discuss possible approaches to predicting whether various cancers will respond to these agents.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d41976e290>Mitochondrial apoptosis and BAX/BAK activation</h2><p class="" id=d41976e293>BH3 mimetics are designed to inhibit anti-apoptotic BCL2 family proteins, leading to BAX and BAK activation<sup><a href="#ref-12">12</a>–<a href="#ref-14">14</a></sup>. Accordingly, recent advances in understanding the functions of various BCL2 family members provide important insight into the therapeutic effects of BH3 mimetics.</p><div class=section><a name=d41976e303 class=n-a></a><h3 class=section-title>Mitochondrial apoptosis</h3><p class="" id=d41976e308>BCL2 family members regulate apoptosis, a distinct form of cell death that plays critical roles in development, immune response, and tissue homeostasis<sup><a href="#ref-15">15</a>–<a href="#ref-17">17</a></sup>. This type of cell death can be triggered through two different pathways depending on the stimulus. The death receptor pathway is initiated through binding of death ligands to certain cell surface receptors. In contrast, the mitochondrial or intrinsic apoptotic pathway involves the release of mitochondrial intermembrane proteins, including cytochrome c and Smac/Diablo, to the cytosol, where they contribute to subsequent apoptotic changes<sup><a href="#ref-18">18</a>–<a href="#ref-20">20</a></sup>. The translocation of these intermembrane proteins is modulated by the BCL2 family of proteins.</p><p class="" id=d41976e325>Based on differences in structure and function, BCL2 family members are divided into three subgroups<sup><a href="#ref-20">20</a>–<a href="#ref-22">22</a></sup>: BAX and BAK, which contain three distinct BCL2 homology (BH) domains and, upon activation, permeabilize the mitochondrial outer membrane (MOM) by forming proteinaceous pores<sup><a href="#ref-23">23</a>–<a href="#ref-26">26</a></sup> or in other ways<sup><a href="#ref-27">27</a>–<a href="#ref-30">30</a></sup>; the anti-apoptotic family members BCL2, BCLX<sub>L</sub>, MCL1, BCLW, and BCL2A1 (also called BFL1 in humans and A1 in mice), which typically contain four BH domains and oppose MOM permeabilization; and the BH3-only proteins BIM, BID, PUMA, NOXA, BAD, BIK, BMF, and HRK, which share homology with other BCL2 family members only in their 15-amino-acid α-helical BH3 domain and induce apoptosis by facilitating BAX and/or BAK activation<sup><a href="#ref-22">22</a></sup>.</p></div><div class=section><a name=d41976e357 class=n-a></a><h3 class=section-title>BAX/BAK activation models</h3><p class="" id=d41976e362>Three different models have been proposed to explain BAX and BAK activation. The direct activation model proposes that certain BH3-only proteins directly interact with BAX and/or BAK to cause a conformational change that leads to BAX/BAK oligomerization and activation<sup><a href="#ref-31">31</a>–<a href="#ref-33">33</a></sup>. In this model, the major role of anti-apoptotic BCL2 family members is to inhibit the BH3-only proteins. The indirect activation model proposes that BAX and BAK are tonically activated but are restrained by anti-apoptotic BCL2 family members<sup><a href="#ref-34">34</a></sup>. In this model, BH3-only proteins induced by various death signals primarily inhibit the anti-apoptotic BCL2 family members, leading to the release of activated BAX and BAK. Finally, the unified model proposes that anti-apoptotic BCL2 family proteins inhibit both BH3-only proteins and activated BAX or BAK<sup><a href="#ref-35">35</a></sup>. In both instances, the exposed BH3 domains of the pro-apoptotic proteins are neutralized by interaction with BH3-binding grooves, extended clefts on the surfaces of anti-apoptotic BCL2 family members<sup><a href="#ref-36">36</a>,<a href="#ref-37">37</a></sup>. The BH3 mimetics described below have been identified and developed based on their ability to occupy the same BH3-binding grooves.</p></div><div class=section><a name=d41976e388 class=n-a></a><h3 class=section-title>Two mechanisms of BH3 mimetic-induced killing</h3><p class="" id=d41976e393>Neutralization of BH3-binding grooves on anti-apoptotic BCL2 family members is not, by itself, sufficient to kill cells. Instead, binding of BH3 mimetics to anti-apoptotic BCL2 family members must result in BAX and/or BAK activation to elicit cell death. This BAX/BAK activation can occur by one of two processes (<a href="#f1">Figure 1</a>).</p><div class="fig panel clearfix"><a name=f1 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/10375/fb437dc7-62ec-4284-8ace-7ca966841fa1_figure1.gif"><img alt="fb437dc7-62ec-4284-8ace-7ca966841fa1_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/10375/fb437dc7-62ec-4284-8ace-7ca966841fa1_figure1.gif"></a><div class=caption><h3>Figure 1. Two models of BH3 mimetic action.</h3><p id=d41976e409>In Model 1 (left), BH3 mimetics are thought to displace activated BIM from anti-apoptotic BCL2 family members, allowing BIM to subsequently activate BAX and BAK<sup><a href="#ref-44">44</a></sup>. In Model 2 (right), BAK and/or BAX are constitutively activated and are displaced from anti-apoptotic BCL2 family members by BH3 mimetics<sup><a href="#ref-46">46</a></sup>. Model 2 is more compatible with recent studies showing that BAK and BAX can be activated in the absence of BH3-only proteins under cell-free conditions<sup><a href="#ref-46">46</a></sup> and in gene-targeted HCT116 cells<sup><a href="#ref-123">123</a></sup>. It is, however, possible that one mode of activation predominates in some cell lines or tissues and the other mode predominates in others. <b>Table below figure,</b> summary of BCL2 subfamilies, their functions, and members.</p></div></div><p class="" id=d41976e435>First, a subset of BH3-only proteins, termed direct activators, can directly activate BAX and BAK. This group of proteins includes BIM, tBID (a cleaved form of BID), and PUMA<sup><a href="#ref-31">31</a>,<a href="#ref-32">32</a>,<a href="#ref-38">38</a></sup>. The role of NOXA as a direct activator has been controversial, with some studies showing activation of BAX or BAK by NOXA protein<sup><a href="#ref-33">33</a>,<a href="#ref-39">39</a></sup> and other studies reporting that NOXA BH3 peptide cannot directly activate BAX or BAK<sup><a href="#ref-40">40</a>–<a href="#ref-42">42</a></sup>. Chen <i>et al.</i> recently reported that interruption of the gene encoding NOXA in cells already lacking BID, BIM, and PUMA causes increased resistance to multiple apoptotic stimuli, suggesting an important role for NOXA in BAX/BAK activation<sup><a href="#ref-43">43</a></sup>. To the extent that BH3-only proteins are constitutively activated but sequestered by anti-apoptotic BCL2 family members<sup><a href="#ref-44">44</a>,<a href="#ref-45">45</a></sup>, displacement of BH3-only proteins by BH3 mimetics can provide a driving force for BAX and BAK activation (<a href="#f1">Figure 1</a>, Model 1).</p><p class="" id=d41976e480>Recent results, however, suggest that an alternative mechanism might also contribute to BH3 mimetic-induced killing. In particular, Chen and coworkers reported that BID/BIM/PUMA/NOXA-deficient cells can still undergo apoptosis after certain treatments such as etoposide or ultraviolet light, suggesting the existence of additional BAX/BAK activation pathways<sup><a href="#ref-43">43</a></sup>. We simultaneously reported that BAK can undergo lipid-dependent autoactivation under cell-free conditions<sup><a href="#ref-46">46</a></sup>. Within intact cells, the extent of constitutive BAK oligomerization (indicative of partial activation) correlated with BAK protein levels across a panel of lymphohematopoietic cell lines. Moreover, BAK knockdown diminished the extent of BAK oligomerization, suggesting concentration-dependent autoactivation <i>in situ</i><sup><a href="#ref-46">46</a></sup>.</p><p class="" id=d41976e498>If BAK undergoes concentration-dependent autoactivation, how can cells with high BAK levels survive? Our further studies demonstrated that constitutively activated BAK is bound to BCLX<sub>L</sub>, MCL1, or less commonly BCL2<sup><a href="#ref-46">46</a></sup>. Based on these observations, BH3 mimetics might be killing cells by displacing partially activated BAK from anti-apoptotic BCL2 family members (<a href="#f1">Figure 1</a>, Model 2). Consistent with this possibility, cells with constitutive BAK·MCL1 complexes were particularly sensitive to the MCL1 antagonist A-1210477, whereas those with constitutive BAK·BCLX<sub>L</sub> complexes were more sensitive to the BCL2/BCLX<sub>L</sub> inhibitor navitoclax<sup><a href="#ref-46">46</a></sup>. In agreement with these observations, mice harboring a BAK mutant with reduced affinity for BCLX<sub>L</sub> had diminished T cells and platelets, suggesting that BCLX<sub>L</sub>-mediated neutralization of constitutively activated BAK is also important for the survival of certain cell lineages <i>in vivo</i><sup><a href="#ref-47">47</a></sup>. In other cells, e.g. human embryonic stem cells, BAX is constitutively activated, likewise conferring sensitivity to BH3 mimetics<sup><a href="#ref-48">48</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d41976e542>Current status of BH3 mimetics</h2><p class="" id=d41976e545>As these complex and highly dynamic interactions between various BCL2 family members were being elucidated, small molecules that could mimic the effects of BH3-only proteins were also being developed. ABT-737, the first compound identified as a bona fide BH3 mimetic<sup><a href="#ref-8">8</a></sup>, exhibited high affinity for BCL2, BCLX<sub>L</sub>, and BCLW (K<sub>d</sub> &lt;1 nM) and lower affinity for MCL1 and A1/BFL1 (K<sub>d</sub> &gt;1000 nM). Although ABT-737 killed cells in a BAX/BAK-dependent manner<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup> and exhibited anti-tumor activity<sup><a href="#ref-8">8</a></sup>, it was not orally bioavailable and displayed poor aqueous solubility, precluding its clinical development.</p><div class=section><a name=d41976e573 class=n-a></a><h3 class=section-title>Navitoclax: inhibitor of BCL2, BCLX<sub>L</sub>, and BCLW</h3><p class="" id=d41976e581>Navitoclax (ABT-263), an orally bioavailable small molecule with a binding profile similar to that of ABT-737<sup><a href="#ref-9">9</a></sup>, also disrupts interactions involving BCL2 and BCLX<sub>L</sub>, causes BAX/BAK-dependent apoptosis <i>in vitro</i>, and induces complete regressions in xenograft models of small-cell lung cancer (SCLC) and acute lymphoblastic leukemia (ALL)<sup><a href="#ref-9">9</a></sup>. In early clinical testing, navitoclax displayed single-agent activity against relapsed/refractory lymphoid malignancies<sup><a href="#ref-10">10</a>,<a href="#ref-51">51</a></sup>, especially CLL. Adding navitoclax to the monoclonal anti-CD20 antibody rituximab improved both response rate and progression-free survival in previously untreated CLL compared to rituximab alone<sup><a href="#ref-52">52</a></sup>. This hypersensitivity of CLL was thought to reflect frequent deletion of genes on chromosome 13q14 encoding miR15A and miR16A, two microRNAs that normally inhibit BCL2 expression<sup><a href="#ref-53">53</a>,<a href="#ref-54">54</a></sup>. Loss of these microRNAs is thought to result in constitutive BCL2 overexpression and BCL2 addiction<sup><a href="#ref-5">5</a>,<a href="#ref-6">6</a>,<a href="#ref-55">55</a></sup>.</p><p class="" id=d41976e627>Unfortunately, navitoclax also acutely induced thrombocytopenia<sup><a href="#ref-10">10</a>,<a href="#ref-51">51</a></sup>, reflecting the role of BCLX<sub>L</sub> in platelet survival<sup><a href="#ref-47">47</a>,<a href="#ref-56">56</a>,<a href="#ref-57">57</a></sup>. Although this thrombocytopenia could be diminished by treating patients with 150 mg navitoclax/day for one week followed by therapeutic does of 325 mg daily<sup><a href="#ref-10">10</a></sup>, maximal BCL2 inhibition was never achieved in lymphoid malignancies because of toxicities of BCLX<sub>L</sub> inhibition in other normal tissues. Moreover, clinical activity of navitoclax in solid tumors was limited. SCLC appeared to respond better than did other tumors<sup><a href="#ref-58">58</a></sup>, but only 3% (one in 39) of patients<sup><a href="#ref-59">59</a></sup> achieved even a partial response (PR). In addition, when navitoclax was combined with other agents, including carboplatin/paclitaxel<sup><a href="#ref-60">60</a></sup>, gemcitabine<sup><a href="#ref-61">61</a></sup>, or irinotecan<sup><a href="#ref-62">62</a></sup>, extensive toxicity and limited efficacy were observed.</p></div><div class=section><a name=d41976e679 class=n-a></a><h3 class=section-title>Venetoclax: a BCL2-selective inhibitor for CLL and beyond</h3><p class="" id=d41976e684>Developed specifically to avoid the thrombocytopenia associated with BCLX<sub>L</sub> inhibition, venetoclax exhibits selectivity for BCL2 over BCLX<sub>L</sub> (K<sub>d</sub> &lt;0.01 nM versus 48 nM, respectively), kills cells in a BAX/BAK-dependent manner, and spares platelets<sup><a href="#ref-11">11</a></sup>. In light of the navitoclax clinical results, the first phase I trial of venetoclax was conducted in relapsed or refractory (R/R) CLL, including CLL with deletions of the short arm of chromosome 17 (17p), where the tumor suppressor gene <i>TP53</i> is located, unmutated <i>IGHV</i>,<i></i> or fludarabine-resistant<i></i> disease<sup><a href="#ref-63">63</a></sup>. Among 116 patients treated, 59% achieved PR and 20% clinical complete remission (CR), including 5% who had no detectable residual disease by flow cytometry. A subsequent single-arm phase II trial demonstrated a 72% PR and 7.5% CR rate in R/R CLL with 17p deletion<sup><a href="#ref-64">64</a></sup>. The major side effect in these trials was tumor lysis syndrome (TLS), which could be minimized by starting at a dose of 20 mg daily and ramping up weekly to 400 mg daily over 5 weeks. These observations led to FDA approval of venetoclax for 17p-deleted CLL in April 2016 (<a target=xrefwindow href="http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm495351.htm" id=d41976e718>http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm495351.htm</a>). However, consistent with the idea that venetoclax, as a BH3 mimetic, should induce apoptosis in a <i>TP53</i>-independent manner, venetoclax kills CLL cells <i>ex vivo</i> regardless of their <i>TP53</i> mutation status<sup><a href="#ref-65">65</a></sup>. Accordingly, a retrospective analysis of <i>TP53</i> status in cases treated in the original phase I trial<sup><a href="#ref-63">63</a></sup> might clarify whether <i>TP53</i> wild-type CLL also responds clinically, which could broaden the indication for venetoclax.</p><p class="" id=d41976e747>Beyond CLL, venetoclax exhibits activity against a variety of lymphoid malignancies. In preclinical studies, concurrent inhibition of BCLX<sub>L</sub> is required for venetoclax to kill most ALL cells<sup><a href="#ref-66">66</a></sup>, the notable exception being MLL-rearranged (MLLr) ALL. In this latter disease, BCL2 is highly expressed because of DOT1L-mediated H3K79 methylation<sup><a href="#ref-67">67</a></sup>, rendering MLLr ALL sensitive to venetoclax alone<sup><a href="#ref-66">66</a>,<a href="#ref-67">67</a></sup>. A clinical trial of venetoclax in MLLr ALL is awaited with interest.</p><p class="" id=d41976e768>Venetoclax is also active against lymphomas. In a phase I trial, venetoclax monotherapy had an overall response rate of 44% (<a href="#T1">Table 1</a>) in various R/R non-Hodgkin lymphomas<sup><a href="#ref-68">68</a></sup>. Addition of the alkylating agent bendamustine and anti-CD20 antibody rituximab resulted in an even more impressive overall response rate in follicular lymphoma, diffuse large B-cell lymphoma, and marginal zone lymphoma (<a href="#T2">Table 2</a>)<sup><a href="#ref-69">69</a></sup>. In combination with the Bruton’s tyrosine kinase inhibitor ibrutinib, venetoclax also induced remissions in R/R mantle cell lymphoma<sup><a href="#ref-70">70</a></sup>.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Efficacy of venetoclax monotherapy in relapsed/refractory NHL<sup><a href="#note-1">a</a></sup>.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d41976e804 class=n-a></a><thead><a name=d41976e806 class=n-a></a><tr><a name=d41976e808 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d41976e810 class=n-a></a>Disease</th><th align=left colspan=1 rowspan=1 valign=top><a name=d41976e813 class=n-a></a>Number</th><th align=left colspan=1 rowspan=1 valign=top><a name=d41976e816 class=n-a></a>OR<sup><a href="#note-2">b</a></sup></th><th align=left colspan=1 rowspan=1 valign=top><a name=d41976e822 class=n-a></a>CR</th><th align=left colspan=1 rowspan=1 valign=top><a name=d41976e825 class=n-a></a>PR</th><th align=left colspan=1 rowspan=1 valign=top><a name=d41976e829 class=n-a></a>Stable</th><th align=left colspan=1 rowspan=1 valign=top><a name=d41976e832 class=n-a></a>PROG</th><th align=left colspan=1 rowspan=1 valign=top><a name=d41976e835 class=n-a></a>Median progression-<br class=br>free survival (months)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d41976e840 class=n-a></a>12-month<br class=br>survival</th></tr></thead><tbody><a name=d41976e847 class=n-a></a><tr><a name=d41976e849 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e851 class=n-a></a>WM</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e854 class=n-a></a>4</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e857 class=n-a></a>100%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e860 class=n-a></a>0%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e863 class=n-a></a>100%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e867 class=n-a></a>0%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e870 class=n-a></a>0%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e873 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e876 class=n-a></a>NR</td></tr><tr><a name=d41976e880 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e882 class=n-a></a>MCL</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e885 class=n-a></a>28</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e888 class=n-a></a>75%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e891 class=n-a></a>21%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e894 class=n-a></a>54%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e898 class=n-a></a>18%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e901 class=n-a></a>4%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e904 class=n-a></a>14</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e907 class=n-a></a>82%</td></tr><tr><a name=d41976e911 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e913 class=n-a></a>MZL</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e916 class=n-a></a>3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e919 class=n-a></a>67%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e922 class=n-a></a>0%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e925 class=n-a></a>67%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e929 class=n-a></a>0%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e932 class=n-a></a>0%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e935 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e938 class=n-a></a>NR</td></tr><tr><a name=d41976e942 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e944 class=n-a></a>DLBCL-RT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e947 class=n-a></a>7</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e950 class=n-a></a>43%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e953 class=n-a></a>0%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e956 class=n-a></a>43%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e960 class=n-a></a>29%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e963 class=n-a></a>14%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e966 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e969 class=n-a></a>NR</td></tr><tr><a name=d41976e973 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e975 class=n-a></a>DLBCL</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e978 class=n-a></a>34</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e981 class=n-a></a>18%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e984 class=n-a></a>12%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e987 class=n-a></a>6%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e991 class=n-a></a>24%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e994 class=n-a></a>56%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e997 class=n-a></a>1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1000 class=n-a></a>34%</td></tr><tr><a name=d41976e1005 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1007 class=n-a></a>FL</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1010 class=n-a></a>29</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1013 class=n-a></a>38%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1016 class=n-a></a>14%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1019 class=n-a></a>24%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1023 class=n-a></a>59%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1026 class=n-a></a>4%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1029 class=n-a></a>11</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1032 class=n-a></a>100%</td></tr><tr><a name=d41976e1036 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1038 class=n-a></a>Total</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1041 class=n-a></a>106</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1044 class=n-a></a>44%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1047 class=n-a></a>13%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1050 class=n-a></a>31%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1054 class=n-a></a>30%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1057 class=n-a></a>22%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1060 class=n-a></a>17</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1063 class=n-a></a>72%</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d41976e1071 class=n-a></a><p id=note-1> <sup>a</sup>Summarized from <a href="#ref-68">68</a>.</p><p id=note-2><sup>b</sup>Abbreviations: CR, complete remission; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; NR, not reported; OR, overall response rate; PR, partial remission, PROG, progressive disease; RT, Richter’s transformation; WM, Waldenstrom’s macroglobulinemia.</p></div></div></div><div class="table-wrap panel clearfix"><a name=T2 class=n-a></a><div class=caption><h3>Table 2. Efficacy of bendamustine/rituximab/venetoclax against NHL<sup><a href="#note-3">a</a></sup>.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d41976e1104 class=n-a></a><thead><a name=d41976e1106 class=n-a></a><tr><a name=d41976e1108 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d41976e1110 class=n-a></a></th><th align=left colspan=1 rowspan=1 valign=top><a name=d41976e1112 class=n-a></a>FL<sup><a href="#note-2">b</a></sup></th><th align=left colspan=1 rowspan=1 valign=top><a name=d41976e1118 class=n-a></a>DLBCL</th><th align=left colspan=1 rowspan=1 valign=top><a name=d41976e1121 class=n-a></a>MZL</th><th align=left colspan=1 rowspan=1 valign=top><a name=d41976e1124 class=n-a></a></th></tr></thead><tbody><a name=d41976e1128 class=n-a></a><tr><a name=d41976e1130 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1132 class=n-a></a>Number of patients</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1135 class=n-a></a>27</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1138 class=n-a></a>16</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1141 class=n-a></a>6</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1144 class=n-a></a></td></tr><tr><a name=d41976e1147 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1149 class=n-a></a>OR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1152 class=n-a></a>78%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1155 class=n-a></a>38%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1158 class=n-a></a>80%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1161 class=n-a></a></td></tr><tr><a name=d41976e1164 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1166 class=n-a></a>CR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1169 class=n-a></a>30%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1172 class=n-a></a>25%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1175 class=n-a></a>20%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1178 class=n-a></a></td></tr><tr><a name=d41976e1181 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1183 class=n-a></a>PR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1186 class=n-a></a>48%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1189 class=n-a></a>13%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1192 class=n-a></a>60%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1195 class=n-a></a></td></tr><tr><a name=d41976e1198 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1200 class=n-a></a>Stable</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1203 class=n-a></a>4%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1206 class=n-a></a>13%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1209 class=n-a></a>0%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1212 class=n-a></a></td></tr><tr><a name=d41976e1216 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1218 class=n-a></a>PROG</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1221 class=n-a></a>7%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1224 class=n-a></a>38%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1227 class=n-a></a>0%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41976e1230 class=n-a></a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d41976e1237 class=n-a></a><p id=note-3> <sup>a</sup>Summarized from <a href="#ref-67">67</a>.</p><p id=note-4><sup>b</sup>Abbreviations: DLBCL, diffuse large B-cell lymphoma; CR, complete remission; FL, follicular lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; OR, overall response; PR, partial remission, PROG, progressive disease.</p></div></div></div><p class="" id=d41976e1253>BCL2 has also been implicated in the survival of multiple myeloma (MM) cells, particularly those with t(11;14) translocation. Accordingly, MMs with this translocation have a higher response rate to venetoclax than those without (24% versus 4%)<sup><a href="#ref-71">71</a></sup>. In addition, a trial of venetoclax in combination with bortezomib and dexamethasone in R/R MM appears promising<sup><a href="#ref-72">72</a></sup>.</p><p class="" id=d41976e1264>Venetoclax has also been extensively studied in acute myelogenous leukemia (AML). A preclinical study suggested that AML is exquisitely sensitive to single-agent venetoclax <i>ex vivo</i><sup><a href="#ref-73">73</a></sup>. A subsequent phase II clinical trial, however, demonstrated responses (CR/CRi) in only six of 32 patients (19%) with R/R AML<sup><a href="#ref-74">74</a></sup>. This somewhat low response rate may be related to the upregulation of BCLX<sub>L</sub> and MCL1 in this disease, particularly at the time of AML relapse<sup><a href="#ref-75">75</a></sup>, as well as other factors such as <i>HOX</i> gene expression<sup><a href="#ref-76">76</a></sup>. Interestingly, combinations of venetoclax with low-dose cytarabine or DNA methyltransferase inhibitors exhibit response rates of 44%<sup><a href="#ref-77">77</a></sup> and 76%<sup><a href="#ref-78">78</a></sup>, respectively, in elderly patients with previously untreated AML, raising the possibility that using venetoclax as a sensitizing agent might be particularly effective in this patient population.</p><p class="" id=d41976e1300>In most solid tumors, BCLX<sub>L</sub> and MCL1 appear to be more important than BCL2 in inhibiting apoptosis<sup><a href="#ref-79">79</a></sup>. However, SCLC<sup><a href="#ref-80">80</a></sup> and estrogen receptor-positive (ER<sup>+</sup>) breast cancer<sup><a href="#ref-81">81</a></sup> exhibit high BCL2 expression and venetoclax sensitivity. Accordingly, clinical studies of venetoclax in these malignancies appear to be warranted but have not yet been initiated.</p></div><div class=section><a name=d41976e1322 class=n-a></a><h3 class=section-title>BCLX<sub>L</sub> inhibitor: WEHI-539</h3><p class="" id=d41976e1330>BCLX<sub>L</sub> is frequently expressed at high levels in solid tumors, including colorectal<sup><a href="#ref-82">82</a></sup>, hormone-refractory prostate<sup><a href="#ref-83">83</a></sup>, and mesenchymal breast cancers<sup><a href="#ref-84">84</a></sup>, conferring chemotherapy resistance<sup><a href="#ref-84">84</a>,<a href="#ref-85">85</a></sup>. A BCLX<sub>L</sub> inhibitor could be particularly useful in treating these cancers. WEHI-539<sup><a href="#ref-86">86</a></sup> and its more potent derivative A-1155463<sup><a href="#ref-87">87</a></sup> selectively and tightly bind to BCLX<sub>L</sub>. In mice, A-1155463 causes reversible on-target thrombocytopenia and inhibits SCLC xenograft growth<sup><a href="#ref-87">87</a></sup>. In addition, WEHI-539 synergizes with carboplatin in ovarian cancer cell lines<sup><a href="#ref-88">88</a></sup> and with doxorubicin in osteosarcoma<sup><a href="#ref-89">89</a></sup>.</p><p class="" id=d41976e1383>Because of the role of BCLX<sub>L</sub> in platelet survival<sup><a href="#ref-47">47</a>,<a href="#ref-56">56</a>,<a href="#ref-57">57</a></sup>, clinical application of a selective BCLX<sub>L</sub> inhibitor could be a challenge. As with navitoclax, a possible lead-in dose of BCLX<sub>L</sub> inhibitor may lower the risk of severe thrombocytopenia, but clinical efficacy might also be compromised because suboptimal BCLX<sub>L</sub> inhibition during the lead-in might facilitate the development of tumor cell tolerance. Therefore, development of an alternative strategy to mitigate thrombocytopenia might be important for the successful application of BCLX<sub>L</sub> inhibitors.</p></div><div class=section><a name=d41976e1414 class=n-a></a><h3 class=section-title>MCL1 inhibitor: A-1210477</h3><p class="" id=d41976e1419>MCL1 is also an attractive target. MCL1 elevation occurs in many tumors<sup><a href="#ref-75">75</a>,<a href="#ref-79">79</a>,<a href="#ref-90">90</a>,<a href="#ref-91">91</a></sup> and is associated with poor prognosis<sup><a href="#ref-92">92</a>–<a href="#ref-98">98</a></sup>. Moreover, MCL1 contributes to therapy resistance<sup><a href="#ref-99">99</a></sup>, especially to ABT-737, navitoclax, and venetoclax<sup><a href="#ref-49">49</a>,<a href="#ref-100">100</a>–<a href="#ref-103">103</a></sup>.</p><p class="" id=d41976e1456>To date, only one MCL1-selective inhibitor, A1210477, has been reported<sup><a href="#ref-102">102</a></sup>. This agent disrupts complexes of MCL1 with BH3-only proteins, kills MCL1-dependent cells, and exhibits synergy with navitoclax <i>in vitro</i><sup><a href="#ref-102">102</a>,<a href="#ref-104">104</a></sup>. Studying an agent with these properties <i>in vivo</i> could potentially be productive.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d41976e1479>Prediction of BH3 mimetic sensitivity or resistance</h2><p class="" id=d41976e1482>Even though venetoclax has substantial activity against 17p-deleted CLL, responses are not universal. In an era of increasing emphasis on precision medicine, there is substantial interest in predicting which cases will respond to venetoclax or other BH3 mimetics and which will not.</p><div class=section><a name=d41976e1485 class=n-a></a><h3 class=section-title>BCL2 family protein levels</h3><p class="" id=d41976e1490>Several groups have reported that chemotherapy sensitivity can be predicted by algorithms that essentially measure levels of anti-apoptotic BCL2 family members, sum the values, and subtract levels of BAX and BAK<sup><a href="#ref-105">105</a>–<a href="#ref-107">107</a></sup>. While this approach detects differences between sensitive and resistant groups of cell lines or tumors, overlap between the groups might make it difficult to use this approach to dictate therapy for individual patients. Moreover, this approach generally fails to take into account endogenous levels of BH3-only proteins and other binding partners that could alter the anti-apoptotic or pro-apoptotic potentials of the proteins assayed.</p><p class="" id=d41976e1500>For assessing venetoclax sensitivity of lymphoid malignancies, the calculation might actually be simpler. Myc-transformed murine lymphomas are sensitive to navitoclax only if they have elevated BCL2<i></i> levels<sup><a href="#ref-107">107</a></sup>. Accordingly, measurement of BCL2 alone might help predict sensitive versus resistant CLL cases. Consistent with this possibility, recent studies have reported that high BCL2 expression correlates with venetoclax sensitivity in neoplastic lymphocytes<sup><a href="#ref-11">11</a>,<a href="#ref-108">108</a></sup>. Whether elevated levels of BCLX<sub>L</sub> or MCL1, either as a consequence of gene amplification<sup><a href="#ref-79">79</a></sup> or other modifications<sup><a href="#ref-109">109</a>,<a href="#ref-110">110</a></sup>, will similarly predict sensitivity to selective antagonists of these two proteins remains to be tested.</p></div><div class=section><a name=d41976e1532 class=n-a></a><h3 class=section-title>BH3 profiling assays</h3><p class="" id=d41976e1537>BH3 profiling involves treating mitochondria with BH3 peptides and measuring cytochrome c release or mitochondrial depolarization as a strategy to predict sensitivity to BH3 mimetics<sup><a href="#ref-111">111</a>,<a href="#ref-112">112</a></sup> or therapies that act through inducing BH3-only proteins<sup><a href="#ref-113">113</a>,<a href="#ref-114">114</a></sup>. Because the BAD BH3 and HRK BH3 domains have different affinities for anti-apoptotic BCL2 family proteins<sup><a href="#ref-44">44</a>,<a href="#ref-115">115</a></sup>, with BAD binding BCL2 and BCLX<sub>L</sub> tightly but HRK binding only BCLX<sub>L</sub>, subtracting the cytochrome c release caused by HRK from that caused by BAD (BAD–HRK) reportedly predicts venetoclax sensitivity<sup><a href="#ref-116">116</a></sup>. Results using this assay suggested that the maturation stage of T-ALLs determines their sensitivity to navitoclax or venetoclax, with most T-ALLs exhibiting navitoclax sensitivity but early T-cell progenitor ALL being sensitive to venetoclax<sup><a href="#ref-116">116</a></sup>. This assay also predicted that a substantial percentage of AMLs would be sensitive to venetoclax<sup><a href="#ref-73">73</a></sup>. In a subsequent phase II study of venetoclax monotherapy in AML, however, BH3 profiling results correlated only weakly with time on study<sup><a href="#ref-74">74</a></sup>, suggesting that determinants of response are more complicated than originally envisioned.</p><p class="" id=d41976e1584>Building on the experience with BH3 profiling, a modified assay called “dynamic BH3 profiling” involves exposure of cells to diluent versus any potential anticancer drug or combination followed by assessment of mitochondrial depolarization by BIM BH3 peptide in permeabilized cells<sup><a href="#ref-117">117</a></sup>. Early experience with this assay in multiple model systems indicates that drug-induced increases in BIM BH3 peptide-induced mitochondrial depolarization after 16 hours of drug exposure correlate with the extent of cell death at 72–96 hours of continuous drug exposure <i>ex vivo</i>. Whether this assay will provide improved ability to predict response to BH3 mimetics in the clinical setting remains to be determined.</p></div><div class=section><a name=d41976e1595 class=n-a></a><h3 class=section-title>Preformed complexes as potential predictors of response</h3><p class="" id=d41976e1600>An alternative approach to predicting BH3 mimetic sensitivity might come from recent studies demonstrating constitutive BAK activation in a variety of cells<sup><a href="#ref-46">46</a>,<a href="#ref-47">47</a></sup>. If BAK is constitutively bound to BCLX<sub>L</sub>, cells are significantly more sensitive to navitoclax, and if BAK is constitutively bound to MCL1, cells are more sensitive to A-1210477<sup><a href="#ref-46">46</a></sup>, suggesting that measurement of preformed BCLX<sub>L</sub>·BAK and MCL1·BAK complexes might provide insight into sensitivity to the respective BH3 mimetics. There is also a correlation between preformed BCL2·BAK complexes and venetoclax sensitivity<sup><a href="#ref-46">46</a></sup>, perhaps reflecting the fact that these complexes, though somewhat less stable, nonetheless form when BCL2 is expressed at high levels or harbors gain-of-function mutations<sup><a href="#ref-118">118</a>,<a href="#ref-119">119</a></sup>. All of these complexes between BAK and anti-apoptotic BCL2 family members can, like complexes between BH3-only proteins and anti-apoptotic BCL2 family members<sup><a href="#ref-44">44</a>,<a href="#ref-45">45</a></sup>, be detected and potentially quantified by immunoprecipitation<sup><a href="#ref-46">46</a></sup>. Because anti-apoptotic BCL2 family members are expressed on the cytoplasmic surfaces of multiple organelles, not just mitochondria<sup><a href="#ref-120">120</a>,<a href="#ref-121">121</a></sup>, it is possible that immunoprecipitation followed by immunoblotting for BAK, BAX, and BH3-only proteins will provide a more complete picture of the cellular balance between pro-apoptotic and anti-apoptotic BCL2 family members than MOM permeabilization analyses alone.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d41976e1654>Opportunities for future development</h2><p class="" id=d41976e1657>While the recent FDA approval of venetoclax marks a milestone in apoptosis research, there is still much work to be done. As mentioned above, the results of single-agent venetoclax trials in <i>TP53</i> wild-type CLL, other lymphoid malignancies, SCLC, and ER<sup>+</sup> breast cancer are awaited with interest. Moreover, further studies examining the optimal use of venetoclax as a chemosensitizing agent are needed.</p><p class="" id=d41976e1666>Based on the observed clinical activity of venetoclax in CLL, the prospect of selectively targeting BCLX<sub>L</sub> and MCL1, especially in cancers with <i>BCLX</i> or <i>MCL1</i> amplification<sup><a href="#ref-79">79</a></sup>, is also appealing. There are, however, substantial obstacles. The role of BCLX<sub>L</sub> in platelet survival and the consequent thrombocytopenia induced by BCLX<sub>L</sub> inhibition hampered the development of navitoclax<sup><a href="#ref-10">10</a></sup>. Whether it will be possible to develop a clinically viable strategy for avoiding or overcoming this on-target side effect with selective BCLX<sub>L</sub> inhibitors remains to be determined. Likewise, it was reported over a decade ago that MCL1 is required for hematopoietic stem cell survival<sup><a href="#ref-122">122</a></sup>. Because it now appears that this might be due to a BH3-binding groove-independent role for MCL1 in oxidative phosphorylation<sup><a href="#ref-106">106</a></sup> rather than the role of MCL1 in apoptosis, it is possible that MCL1-selective BH3 mimetics will not be as toxic to normal cells as <i>MCL1</i> gene disruption. The development of an MCL1 inhibitor that can be applied in preclinical tumor models and possibly in clinical trials would allow this hypothesis to be tested.</p><p class="" id=d41976e1707>Finally, a substantial fraction of tumors might be resistant to selective BCL2, BCLX<sub>L</sub>, or MCL1 inhibitors. To the extent that these agents act by releasing partially activated BAK or BAX from pre-formed complexes<sup><a href="#ref-46">46</a></sup>, cells lacking activated BAK and BAX will experience little or no effect from these inhibitors. One strategy for sensitizing these cells to BH3 mimetics would be to treat with chemotherapeutic agents that activate BH3-only proteins, leading to BAK or BAX activation<sup><a href="#ref-46">46</a></sup>. Alternatively, it might be possible to induce apoptosis in these cells using BH3 mimetics that directly activate BAK and/or BAX. Whether it will be possible to derive such compounds and target them in a way that allows cancer cell-selective killing also remains to be determined.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d41976e1 class=n-a></a><h2 class=main-title id=d42386>Competing interests</h2><p class=metadata-entry><a name=d41976e157 class=n-a></a><p id=d41976e158> The authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d41976e1 class=n-a></a><h2 class=main-title id=d42388>Grant information</h2><p>Preparation of this review was supported in part by a grant from the NIH (R01 CA166741). Haiming Dai is also supported by the Hundred-Talent Program of the Chinese Academy of Sciences.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d41976e1725 class=n-a></a><h2 class=main-title id=d41976e1727>Acknowledgments</h2><p class="" id=d41976e1730>We thank members of the Kaufmann lab for provocative discussions and Deb Strauss for editorial assistance. We also apologize to many colleagues whose important contributions could not be highlighted because of space limitations.</p></div><div class=back-section><a name=d41976e1734 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d42803>References</h2><div class="section ref-list"><a name=d41976e1734 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d41976e1741 class=n-a></a>Tsujimoto Y, Cossman J, Jaffe E, <i> et al.</i>: Involvement of the bcl-2 gene in human follicular lymphoma. <i>Science.</i> 1985; <b>228</b>(4706): 1440–3. <a target=xrefwindow id=d41976e1752 href="http://www.ncbi.nlm.nih.gov/pubmed/3874430">PubMed Abstract </a> | <a target=xrefwindow id=d41976e1755 href="http://dx.doi.org/10.1126/science.3874430">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d41976e1764 class=n-a></a>Cleary ML, Smith SD, Sklar J: Cloning and structural analysis of cDNAs for <i>bcl</i>-2 and a hybrid <i>bcl</i>-2/immunoglobulin transcript resulting from the t(14;18) translocation. <i>Cell.</i> 1986; <b>47</b>(1): 19–28. <a target=xrefwindow id=d41976e1778 href="http://www.ncbi.nlm.nih.gov/pubmed/2875799">PubMed Abstract </a> | <a target=xrefwindow id=d41976e1782 href="http://dx.doi.org/10.1016/0092-8674(86)90362-4">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d41976e1791 class=n-a></a>Vaux DL, Cory S, Adams JM: <i>Bcl-2</i> gene promotes haemopoietic cell survival and cooperates with <i>c-myc</i> to immortalize pre-B cells. <i>Nature.</i> 1988; <b>335</b>(6189): 440–2. <a target=xrefwindow id=d41976e1805 href="http://www.ncbi.nlm.nih.gov/pubmed/3262202">PubMed Abstract </a> | <a target=xrefwindow id=d41976e1809 href="http://dx.doi.org/10.1038/335440a0">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d41976e1818 class=n-a></a>Strasser A, Harris AW, Cory S: <i>bcl</i>-2 transgene inhibits T cell death and perturbs thymic self-censorship. <i>Cell.</i> 1991; <b>67</b>(5): 889–99. <a target=xrefwindow id=d41976e1829 href="http://www.ncbi.nlm.nih.gov/pubmed/1959134">PubMed Abstract </a> | <a target=xrefwindow id=d41976e1832 href="http://dx.doi.org/10.1016/0092-8674(91)90362-3">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d41976e1841 class=n-a></a>Hanada M, Delia D, Aiello A, <i> et al.</i>: <i>bcl-2</i> gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. <i>Blood.</i> 1993; <b>82</b>(6): 1820–8. <a target=xrefwindow id=d41976e1855 href="http://www.ncbi.nlm.nih.gov/pubmed/8104532">PubMed Abstract </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d41976e1865 class=n-a></a>Robertson LE, Plunkett W, McConnell K, <i> et al.</i>: Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. <i>Leukemia.</i> 1996; <b>10</b>(3): 456–9. <a target=xrefwindow id=d41976e1876 href="http://www.ncbi.nlm.nih.gov/pubmed/8642861">PubMed Abstract </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d41976e1885 class=n-a></a>Sattler M, Liang H, Nettesheim D, <i> et al.</i>: Structure of Bcl-x<sub>L</sub>-Bak peptide complex: recognition between regulators of apoptosis. <i>Science.</i> 1997; <b>275</b>(5302): 983–6. <a target=xrefwindow id=d41976e1899 href="http://www.ncbi.nlm.nih.gov/pubmed/9020082">PubMed Abstract </a> | <a target=xrefwindow id=d41976e1903 href="http://dx.doi.org/10.1126/science.275.5302.983">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1026512"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e1912 class=n-a></a>Oltersdorf T, Elmore SW, Shoemaker AR, <i> et al.</i>: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. <i>Nature.</i> 2005; <b>435</b>(7042): 677–81. <a target=xrefwindow id=d41976e1923 href="http://www.ncbi.nlm.nih.gov/pubmed/15902208">PubMed Abstract </a> | <a target=xrefwindow id=d41976e1926 href="http://dx.doi.org/10.1038/nature03579">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1026512">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d41976e1939 class=n-a></a>Tse C, Shoemaker AR, Adickes J, <i> et al.</i>: ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. <i>Cancer Res.</i> 2008; <b>68</b>(9): 3421–8. <a target=xrefwindow id=d41976e1950 href="http://www.ncbi.nlm.nih.gov/pubmed/18451170">PubMed Abstract </a> | <a target=xrefwindow id=d41976e1953 href="http://dx.doi.org/10.1158/0008-5472.CAN-07-5836">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d41976e1962 class=n-a></a>Roberts AW, Seymour JF, Brown JR, <i> et al.</i>: Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. <i>J Clin Oncol.</i> 2012; <b>30</b>(5): 488–96. <a target=xrefwindow id=d41976e1973 href="http://www.ncbi.nlm.nih.gov/pubmed/22184378">PubMed Abstract </a> | <a target=xrefwindow id=d41976e1976 href="http://dx.doi.org/10.1200/JCO.2011.34.7898">Publisher Full Text </a> | <a target=xrefwindow id=d41976e1980 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4979082">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717973247"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e1989 class=n-a></a>Souers AJ, Leverson JD, Boghaert ER, <i> et al.</i>: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. <i>Nat Med.</i> 2013; <b>19</b>(2): 202–8. <a target=xrefwindow id=d41976e2000 href="http://www.ncbi.nlm.nih.gov/pubmed/23291630">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2003 href="http://dx.doi.org/10.1038/nm.3048">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717973247">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d41976e2017 class=n-a></a>Ni Chonghaile T, Letai A: Mimicking the BH3 domain to kill cancer cells. <i>Oncogene.</i> 2008; <b>27</b>(Suppl 1): S149–57. <a target=xrefwindow id=d41976e2025 href="http://www.ncbi.nlm.nih.gov/pubmed/19641500">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2028 href="http://dx.doi.org/10.1038/onc.2009.52">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2031 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3733265">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d41976e2040 class=n-a></a>Strasser A, Cory S, Adams JM: Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. <i>EMBO J.</i> 2011; <b>30</b>(18): 3667–83. <a target=xrefwindow id=d41976e2048 href="http://www.ncbi.nlm.nih.gov/pubmed/21863020">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2051 href="http://dx.doi.org/10.1038/emboj.2011.307">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2054 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3173800">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d41976e2063 class=n-a></a>Anderson MA, Huang D, Roberts A: Targeting BCL2 for the treatment of lymphoid malignancies. <i>Semin Hematol.</i> 2014; <b>51</b>(3): 219–27. <a target=xrefwindow id=d41976e2071 href="http://www.ncbi.nlm.nih.gov/pubmed/25048785">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2074 href="http://dx.doi.org/10.1053/j.seminhematol.2014.05.008">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d41976e2083 class=n-a></a>Martinou JC, Youle RJ: Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. <i>Dev Cell.</i> 2011; <b>21</b>(1): 92–101. <a target=xrefwindow id=d41976e2091 href="http://www.ncbi.nlm.nih.gov/pubmed/21763611">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2094 href="http://dx.doi.org/10.1016/j.devcel.2011.06.017">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2097 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3156409">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d41976e2106 class=n-a></a>Fuchs Y, Steller H: Programmed cell death in animal development and disease. <i>Cell.</i> 2011; <b>147</b>(4): 742–58. <a target=xrefwindow id=d41976e2114 href="http://www.ncbi.nlm.nih.gov/pubmed/22078876">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2117 href="http://dx.doi.org/10.1016/j.cell.2011.10.033">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2120 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4511103">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d41976e2129 class=n-a></a>Hyman BT, Yuan J: Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. <i>Nat Rev Neurosci.</i> 2012; <b>13</b>(6): 395–406. <a target=xrefwindow id=d41976e2137 href="http://www.ncbi.nlm.nih.gov/pubmed/22595785">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2140 href="http://dx.doi.org/10.1038/nrn3228">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d41976e2150 class=n-a></a>Jiang X, Wang X: Cytochrome C-mediated apoptosis. <i>Annu Rev Biochem.</i> 2004; <b>73</b>: 87–106. <a target=xrefwindow id=d41976e2158 href="http://www.ncbi.nlm.nih.gov/pubmed/15189137">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2161 href="http://dx.doi.org/10.1146/annurev.biochem.73.011303.073706">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d41976e2170 class=n-a></a>Ekert PG, Vaux DL: The mitochondrial death squad: hardened killers or innocent bystanders? <i>Curr Opin Cell Biol.</i> 2005; <b>17</b>(6): 626–30. <a target=xrefwindow id=d41976e2178 href="http://www.ncbi.nlm.nih.gov/pubmed/16219456">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2181 href="http://dx.doi.org/10.1016/j.ceb.2005.09.001">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d41976e2190 class=n-a></a>Taylor RC, Cullen SP, Martin SJ: Apoptosis: controlled demolition at the cellular level. <i>Nat Rev Mol Cell Biol.</i> 2008; <b>9</b>(3): 231–41. <a target=xrefwindow id=d41976e2198 href="http://www.ncbi.nlm.nih.gov/pubmed/18073771">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2201 href="http://dx.doi.org/10.1038/nrm2312">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d41976e2210 class=n-a></a>Cory S, Adams JM: The Bcl2 family: regulators of the cellular life-or-death switch. <i>Nat Rev Cancer.</i> 2002; <b>2</b>(9): 647–56. <a target=xrefwindow id=d41976e2218 href="http://www.ncbi.nlm.nih.gov/pubmed/12209154">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2221 href="http://dx.doi.org/10.1038/nrc883">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d41976e2230 class=n-a></a>Czabotar PE, Lessene G, Strasser A, <i> et al.</i>: Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. <i>Nat Rev Mol Cell Biol.</i> 2014; <b>15</b>(1): 49–63. <a target=xrefwindow id=d41976e2241 href="http://www.ncbi.nlm.nih.gov/pubmed/24355989">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2244 href="http://dx.doi.org/10.1038/nrm3722">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d41976e2253 class=n-a></a>Antonsson B, Conti F, Ciavatta A, <i> et al.</i>: Inhibition of Bax channel-forming activity by Bcl-2. <i>Science.</i> 1997; <b>277</b>(5324): 370–2. <a target=xrefwindow id=d41976e2264 href="http://www.ncbi.nlm.nih.gov/pubmed/9219694">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2267 href="http://dx.doi.org/10.1126/science.277.5324.370">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d41976e2277 class=n-a></a>Ma S, Hockings C, Anwari K, <i> et al.</i>: Assembly of the Bak apoptotic pore: a critical role for the Bak protein α6 helix in the multimerization of homodimers during apoptosis. <i>J Biol Chem.</i> 2013; <b>288</b>(36): 26027–38. <a target=xrefwindow id=d41976e2288 href="http://www.ncbi.nlm.nih.gov/pubmed/23893415">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2291 href="http://dx.doi.org/10.1074/jbc.M113.490094">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2295 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3764807">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726084558"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e2304 class=n-a></a>Salvador-Gallego R, Mund M, Cosentino K, <i> et al.</i>: Bax assembly into rings and arcs in apoptotic mitochondria is linked to membrane pores. <i>EMBO J.</i> 2016; <b>35</b>(4): 389–401. <a target=xrefwindow id=d41976e2315 href="http://www.ncbi.nlm.nih.gov/pubmed/26783362">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2318 href="http://dx.doi.org/10.15252/embj.201593384">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2322 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4755116">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726084558">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726084556"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e2335 class=n-a></a>Große L, Wurm CA, Brüser C, <i> et al.</i>: Bax assembles into large ring-like structures remodeling the mitochondrial outer membrane in apoptosis. <i>EMBO J.</i> 2016; <b>35</b>(4): 402–13. <a target=xrefwindow id=d41976e2346 href="http://www.ncbi.nlm.nih.gov/pubmed/26783364">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2349 href="http://dx.doi.org/10.15252/embj.201592789">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2353 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4755111">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726084556">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d41976e2366 class=n-a></a>Basañez G, Nechushtan A, Drozhinin O, <i> et al.</i>: Bax, but not Bcl-x<sub>L</sub>, decreases the lifetime of planar phospholipid bilayer membranes at subnanomolar concentrations. <i>Proc Natl Acad Sci U S A.</i> 1999; <b>96</b>(10): 5492–7. <a target=xrefwindow id=d41976e2380 href="http://www.ncbi.nlm.nih.gov/pubmed/10318911">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2384 href="http://dx.doi.org/10.1073/pnas.96.10.5492">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2387 href="http://www.ncbi.nlm.nih.gov/pmc/articles/21887">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d41976e2396 class=n-a></a>Terrones O, Etxebarria A, Landajuela A, <i> et al.</i>: BIM and tBID are not mechanistically equivalent when assisting BAX to permeabilize bilayer membranes. <i>J Biol Chem.</i> 2008; <b>283</b>(12): 7790–803. <a target=xrefwindow id=d41976e2407 href="http://www.ncbi.nlm.nih.gov/pubmed/18195012">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2410 href="http://dx.doi.org/10.1074/jbc.M708814200">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d41976e2419 class=n-a></a>Westphal D, Dewson G, Menard M, <i> et al.</i>: Apoptotic pore formation is associated with in-plane insertion of Bak or Bax central helices into the mitochondrial outer membrane. <i>Proc Natl Acad Sci U S A.</i> 2014; <b>111</b>(39): E4076–85. <a target=xrefwindow id=d41976e2430 href="http://www.ncbi.nlm.nih.gov/pubmed/25228770">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2433 href="http://dx.doi.org/10.1073/pnas.1415142111">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2437 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4191798">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d41976e2447 class=n-a></a>Kuwana T, Olson NH, Kiosses WB, <i> et al.</i>: Pro-apoptotic Bax molecules densely populate the edges of membrane pores. <i>Sci Rep.</i> 2016; <b>6</b>: 27299. <a target=xrefwindow id=d41976e2458 href="http://www.ncbi.nlm.nih.gov/pubmed/27255832">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2461 href="http://dx.doi.org/10.1038/srep27299">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2465 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4891688">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1009339"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e2474 class=n-a></a>Letai A, Bassik MC, Walensky LD, <i> et al.</i>: Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. <i>Cancer Cell.</i> 2002; <b>2</b>(3): 183–92. <a target=xrefwindow id=d41976e2485 href="http://www.ncbi.nlm.nih.gov/pubmed/12242151">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2488 href="http://dx.doi.org/10.1016/S1535-6108(02)00127-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1009339">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1024156"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e2501 class=n-a></a>Kuwana T, Bouchier-Hayes L, Chipuk JE, <i> et al.</i>: BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. <i>Mol Cell.</i> 2005; <b>17</b>(4): 525–35. <a target=xrefwindow id=d41976e2512 href="http://www.ncbi.nlm.nih.gov/pubmed/15721256">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2515 href="http://dx.doi.org/10.1016/j.molcel.2005.02.003">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1024156">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/11941956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e2528 class=n-a></a>Dai H, Smith A, Meng XW, <i> et al.</i>: Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. <i>J Cell Biol.</i> 2011; <b>194</b>(1): 39–48. <a target=xrefwindow id=d41976e2539 href="http://www.ncbi.nlm.nih.gov/pubmed/21727192">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2542 href="http://dx.doi.org/10.1083/jcb.201102027">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2546 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3135403">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/11941956">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1066003"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e2559 class=n-a></a>Willis SN, Fletcher JI, Kaufmann T, <i> et al.</i>: Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. <i>Science.</i> 2007; <b>315</b>(5813): 856–9. <a target=xrefwindow id=d41976e2570 href="http://www.ncbi.nlm.nih.gov/pubmed/17289999">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2573 href="http://dx.doi.org/10.1126/science.1133289">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1066003">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/13360079"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e2586 class=n-a></a>Llambi F, Moldoveanu T, Tait SW, <i> et al.</i>: A unified model of mammalian BCL-2 protein family interactions at the mitochondria. <i>Mol Cell.</i> 2011; <b>44</b>(4): 517–31. <a target=xrefwindow id=d41976e2597 href="http://www.ncbi.nlm.nih.gov/pubmed/22036586">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2600 href="http://dx.doi.org/10.1016/j.molcel.2011.10.001">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2604 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3221787">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/13360079">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d41976e2618 class=n-a></a>Muchmore SW, Sattler M, Liang H, <i> et al.</i>: X-ray and NMR structure of human Bcl-x<sub>L</sub>, an inhibitor of programmed cell death. <i>Nature.</i> 1996; <b>381</b>(6580): 335–41. <a target=xrefwindow id=d41976e2632 href="http://www.ncbi.nlm.nih.gov/pubmed/8692274">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2636 href="http://dx.doi.org/10.1038/381335a0">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d41976e2645 class=n-a></a>Petros AM, Medek A, Nettesheim DG, <i> et al.</i>: Solution structure of the antiapoptotic protein bcl-2. <i>Proc Natl Acad Sci U S A.</i> 2001; <b>98</b>(6): 3012–7. <a target=xrefwindow id=d41976e2656 href="http://www.ncbi.nlm.nih.gov/pubmed/11248023">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2659 href="http://dx.doi.org/10.1073/pnas.041619798">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2663 href="http://www.ncbi.nlm.nih.gov/pmc/articles/30598">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d41976e2672 class=n-a></a>Dai H, Pang Y, Ramirez-Alvarado M, <i> et al.</i>: Evaluation of the BH3-only protein Puma as a direct Bak activator. <i>J Biol Chem.</i> 2014; <b>289</b>(1): 89–99. <a target=xrefwindow id=d41976e2683 href="http://www.ncbi.nlm.nih.gov/pubmed/24265320">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2686 href="http://dx.doi.org/10.1074/jbc.M113.505701">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2690 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3879582">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718913967"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e2699 class=n-a></a>Du H, Wolf J, Schafer B, <i> et al.</i>: BH3 domains other than Bim and Bid can directly activate Bax/Bak. <i>J Biol Chem.</i> 2011; <b>286</b>(1): 491–501. <a target=xrefwindow id=d41976e2710 href="http://www.ncbi.nlm.nih.gov/pubmed/21041309">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2713 href="http://dx.doi.org/10.1074/jbc.M110.167148">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2717 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3013008">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718913967">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718001946"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e2730 class=n-a></a>Moldoveanu T, Grace CR, Llambi F, <i> et al.</i>: BID-induced structural changes in BAK promote apoptosis. <i>Nat Struct Mol Biol.</i> 2013; <b>20</b>(5): 589–97. <a target=xrefwindow id=d41976e2741 href="http://www.ncbi.nlm.nih.gov/pubmed/23604079">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2744 href="http://dx.doi.org/10.1038/nsmb.2563">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2748 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3683554">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718001946">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717988214"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e2761 class=n-a></a>Czabotar PE, Westphal D, Dewson G, <i> et al.</i>: Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. <i>Cell.</i> 2013; <b>152</b>(3): 519–31. <a target=xrefwindow id=d41976e2772 href="http://www.ncbi.nlm.nih.gov/pubmed/23374347">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2775 href="http://dx.doi.org/10.1016/j.cell.2012.12.031">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717988214">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718552096"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e2789 class=n-a></a>Brouwer JM, Westphal D, Dewson G, <i> et al.</i>: Bak core and latch domains separate during activation, and freed core domains form symmetric homodimers. <i>Mol Cell.</i> 2014; <b>55</b>(6): 938–46. <a target=xrefwindow id=d41976e2800 href="http://www.ncbi.nlm.nih.gov/pubmed/25175025">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2803 href="http://dx.doi.org/10.1016/j.molcel.2014.07.016">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718552096">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725773056"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e2816 class=n-a></a>Chen HC, Kanai M, Inoue-Yamauchi A, <i> et al.</i>: An interconnected hierarchical model of cell death regulation by the BCL-2 family. <i>Nat Cell Biol.</i> 2015; <b>17</b>(10): 1270–81. <a target=xrefwindow id=d41976e2827 href="http://www.ncbi.nlm.nih.gov/pubmed/26344567">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2830 href="http://dx.doi.org/10.1038/ncb3236">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2834 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4589531">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725773056">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d41976e2847 class=n-a></a>Certo M, Del Gaizo Moore V, Nishino M, <i> et al.</i>: Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. <i>Cancer Cell.</i> 2006; <b>9</b>(5): 351–65. <a target=xrefwindow id=d41976e2858 href="http://www.ncbi.nlm.nih.gov/pubmed/16697956">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2861 href="http://dx.doi.org/10.1016/j.ccr.2006.03.027">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d41976e2870 class=n-a></a>Dai H, Ding H, Meng XW, <i> et al.</i>: Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance. <i>Cancer Res.</i> 2013; <b>73</b>(23): 6998–7008. <a target=xrefwindow id=d41976e2881 href="http://www.ncbi.nlm.nih.gov/pubmed/24097825">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2884 href="http://dx.doi.org/10.1158/0008-5472.CAN-13-0940">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2888 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3910374">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d41976e2897 class=n-a></a>Dai H, Ding H, Meng XW, <i> et al.</i>: Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells. <i>Genes Dev.</i> 2015; <b>29</b>(20): 2140–52. <a target=xrefwindow id=d41976e2908 href="http://www.ncbi.nlm.nih.gov/pubmed/26494789">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2911 href="http://dx.doi.org/10.1101/gad.267997.115">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2915 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4617978">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726369624"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e2924 class=n-a></a>Lee EF, Grabow S, Chappaz S, <i> et al.</i>: Physiological restraint of Bak by Bcl-x<sub>L</sub> is essential for cell survival. <i>Genes Dev.</i> 2016; <b>30</b>(10): 1240–50. <a target=xrefwindow id=d41976e2938 href="http://www.ncbi.nlm.nih.gov/pubmed/27198225">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2942 href="http://dx.doi.org/10.1101/gad.279414.116">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2945 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4888843">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726369624">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d41976e2959 class=n-a></a>Dumitru R, Gama V, Fagan BM, <i> et al.</i>: Human embryonic stem cells have constitutively active Bax at the Golgi and are primed to undergo rapid apoptosis. <i>Mol Cell.</i> 2012; <b>46</b>(5): 573–83. <a target=xrefwindow id=d41976e2970 href="http://www.ncbi.nlm.nih.gov/pubmed/22560721">PubMed Abstract </a> | <a target=xrefwindow id=d41976e2973 href="http://dx.doi.org/10.1016/j.molcel.2012.04.002">Publisher Full Text </a> | <a target=xrefwindow id=d41976e2977 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3372694">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1053003"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e2986 class=n-a></a>van Delft MF, Wei AH, Mason KD, <i> et al.</i>: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. <i>Cancer Cell.</i> 2006; <b>10</b>(5): 389–99. <a target=xrefwindow id=d41976e2997 href="http://www.ncbi.nlm.nih.gov/pubmed/17097561">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3000 href="http://dx.doi.org/10.1016/j.ccr.2006.08.027">Publisher Full Text </a> | <a target=xrefwindow id=d41976e3004 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2953559">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1053003">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1160279"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3017 class=n-a></a>Vogler M, Weber K, Dinsdale D, <i> et al.</i>: Different forms of cell death induced by putative BCL2 inhibitors. <i>Cell Death Differ.</i> 2009; <b>16</b>(7): 1030–9. <a target=xrefwindow id=d41976e3028 href="http://www.ncbi.nlm.nih.gov/pubmed/19390557">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3031 href="http://dx.doi.org/10.1038/cdd.2009.48">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1160279">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d41976e3044 class=n-a></a>Chiappori AA, Schreeder MT, Moezi MM, <i> et al.</i>: A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. <i>Br J Cancer.</i> 2012; <b>106</b>(5): 839–45. <a target=xrefwindow id=d41976e3055 href="http://www.ncbi.nlm.nih.gov/pubmed/22333598">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3058 href="http://dx.doi.org/10.1038/bjc.2012.21">Publisher Full Text </a> | <a target=xrefwindow id=d41976e3062 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3305978">Free Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725400916"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3071 class=n-a></a>Kipps TJ, Eradat H, Grosicki S, <i> et al.</i>: A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. <i>Leuk Lymphoma.</i> 2015; <b>56</b>(10): 2826–33. <a target=xrefwindow id=d41976e3082 href="http://www.ncbi.nlm.nih.gov/pubmed/25797560">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3085 href="http://dx.doi.org/10.3109/10428194.2015.1030638">Publisher Full Text </a> | <a target=xrefwindow id=d41976e3089 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4643417">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725400916">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1028291"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3102 class=n-a></a>Cimmino A, Calin GA, Fabbri M, <i> et al.</i>: <i>miR-15</i> and <i>miR-16</i> induce apoptosis by targeting BCL2. <i>Proc Natl Acad Sci U S A.</i> 2005; <b>102</b>(39): 13944–9. <a target=xrefwindow id=d41976e3120 href="http://www.ncbi.nlm.nih.gov/pubmed/16166262">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3123 href="http://dx.doi.org/10.1073/pnas.0506654102">Publisher Full Text </a> | <a target=xrefwindow id=d41976e3126 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1236577">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1028291">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/2174956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3140 class=n-a></a>Klein U, Lia M, Crespo M, <i> et al.</i>: The <i>DLEU2/miR-15a/16-1</i> cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. <i>Cancer Cell.</i> 2010; <b>17</b>(1): 28–40. <a target=xrefwindow id=d41976e3154 href="http://www.ncbi.nlm.nih.gov/pubmed/20060366">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3158 href="http://dx.doi.org/10.1016/j.ccr.2009.11.019">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/2174956">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1066064"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3171 class=n-a></a>Del Gaizo Moore V, Brown JR, Certo M, <i> et al.</i>: Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. <i>J Clin Invest.</i> 2007; <b>117</b>(1): 112–21. <a target=xrefwindow id=d41976e3182 href="http://www.ncbi.nlm.nih.gov/pubmed/17200714">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3185 href="http://dx.doi.org/10.1172/JCI28281">Publisher Full Text </a> | <a target=xrefwindow id=d41976e3189 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1716201">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1066064">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1071045"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3202 class=n-a></a>Mason KD, Carpinelli MR, Fletcher JI, <i> et al.</i>: Programmed anuclear cell death delimits platelet life span. <i>Cell.</i> 2007; <b>128</b>(6): 1173–86. <a target=xrefwindow id=d41976e3213 href="http://www.ncbi.nlm.nih.gov/pubmed/17382885">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3216 href="http://dx.doi.org/10.1016/j.cell.2007.01.037">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1071045">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d41976e3229 class=n-a></a>Josefsson EC, White MJ, Dowling MR, <i> et al.</i>: Platelet life span and apoptosis. <i>Methods Mol Biol.</i> 2012; <b>788</b>: 59–71. <a target=xrefwindow id=d41976e3240 href="http://www.ncbi.nlm.nih.gov/pubmed/22130700">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3243 href="http://dx.doi.org/10.1007/978-1-61779-307-3_5">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d41976e3252 class=n-a></a>Gandhi L, Camidge DR, Ribeiro de Oliveira M, <i> et al.</i>: Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. <i>J Clin Oncol.</i> 2011; <b>29</b>(7): 909–16. <a target=xrefwindow id=d41976e3263 href="http://www.ncbi.nlm.nih.gov/pubmed/21282543">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3266 href="http://dx.doi.org/10.1200/JCO.2010.31.6208">Publisher Full Text </a> | <a target=xrefwindow id=d41976e3270 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4668282">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d41976e3279 class=n-a></a>Rudin CM, Hann CL, Garon EB, <i> et al.</i>: Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. <i>Clin Cancer Res.</i> 2012; <b>18</b>(11): 3163–9. <a target=xrefwindow id=d41976e3290 href="http://www.ncbi.nlm.nih.gov/pubmed/22496272">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3293 href="http://dx.doi.org/10.1158/1078-0432.CCR-11-3090">Publisher Full Text </a> | <a target=xrefwindow id=d41976e3297 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3715059">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d41976e3307 class=n-a></a>Vlahovic G, Karantza V, Wang D, <i> et al.</i>: A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors. <i>Invest New Drugs.</i> 2014; <b>32</b>(5): 976–84. <a target=xrefwindow id=d41976e3318 href="http://www.ncbi.nlm.nih.gov/pubmed/24894650">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3321 href="http://dx.doi.org/10.1007/s10637-014-0116-3">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726978662"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3330 class=n-a></a>Cleary JM, Lima CM, Hurwitz HI, <i> et al.</i>: A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. <i>Invest New Drugs.</i> 2014; <b>32</b>(5): 937–45. <a target=xrefwindow id=d41976e3341 href="http://www.ncbi.nlm.nih.gov/pubmed/24916770">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3344 href="http://dx.doi.org/10.1007/s10637-014-0110-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726978662">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726978664"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3357 class=n-a></a>Tolcher AW, LoRusso P, Arzt J, <i> et al.</i>: Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study. <i>Cancer Chemother Pharmacol.</i> 2015; <b>76</b>(5): 1041–9. <a target=xrefwindow id=d41976e3368 href="http://www.ncbi.nlm.nih.gov/pubmed/26429709">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3371 href="http://dx.doi.org/10.1007/s00280-015-2882-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726978664">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725994198"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3384 class=n-a></a>Roberts AW, Davids MS, Pagel JM, <i> et al.</i>: Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>N Engl J Med.</i> 2016; <b>374</b>(4): 311–22. <a target=xrefwindow id=d41976e3395 href="http://www.ncbi.nlm.nih.gov/pubmed/26639348">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3398 href="http://dx.doi.org/10.1056/NEJMoa1513257">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725994198">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726356653"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3411 class=n-a></a>Stilgenbauer S, Eichhorst B, Schetelig J, <i> et al.</i>: Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. <i>Lancet Oncol.</i> 2016; <b>17</b>(6): 768–78. <a target=xrefwindow id=d41976e3422 href="http://www.ncbi.nlm.nih.gov/pubmed/27178240">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3425 href="http://dx.doi.org/10.1016/S1470-2045(16)30019-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726356653">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726281749"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3438 class=n-a></a>Anderson MA, Deng J, Seymour JF, <i> et al.</i>: The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. <i>Blood.</i> 2016; <b>127</b>(25): 3215–24. <a target=xrefwindow id=d41976e3449 href="http://www.ncbi.nlm.nih.gov/pubmed/27069256">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3452 href="http://dx.doi.org/10.1182/blood-2016-01-688796">Publisher Full Text </a> | <a target=xrefwindow id=d41976e3456 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4920022">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726281749">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726465378"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3470 class=n-a></a>Khaw SL, Suryani S, Evans K, <i> et al.</i>: Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. <i>Blood.</i> 2016; <b>128</b>(10): 1382–95. <a target=xrefwindow id=d41976e3481 href="http://www.ncbi.nlm.nih.gov/pubmed/27343252">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3484 href="http://dx.doi.org/10.1182/blood-2016-03-707414">Publisher Full Text </a> | <a target=xrefwindow id=d41976e3488 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5016707">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726465378">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726044430"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3501 class=n-a></a>Benito JM, Godfrey L, Kojima K, <i> et al.</i>: MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. <i>Cell Rep.</i> 2015; <b>13</b>(12): 2715–27. <a target=xrefwindow id=d41976e3512 href="http://www.ncbi.nlm.nih.gov/pubmed/26711339">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3515 href="http://dx.doi.org/10.1016/j.celrep.2015.12.003">Publisher Full Text </a> | <a target=xrefwindow id=d41976e3519 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4700051">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726044430">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d41976e3532 class=n-a></a>Gerecitano JF, Roberts AW, Seymour JF, <i> et al.</i>: A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Blood.</i> 2015; <b>126</b>(23): 254. <a target=xrefwindow id=d41976e3543 href="http://www.bloodjournal.org/content/126/23/254?sso-checked=true">Reference Source</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d41976e3552 class=n-a></a>de Vos S, Swinnen L, Kozloff M, <i> et al.</i>: A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma. <i>Blood.</i> 2015; <b>126</b>(23): 255. <a target=xrefwindow id=d41976e3563 href="http://www.bloodjournal.org/content/126/23/255">Reference Source</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d41976e3572 class=n-a></a>Tam CSL, Roberts AW, Anderson MA, <i> et al.</i>: The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study. <i>J Clin Oncol.</i> 2016; <b>34</b>(suppl): absract 7548. <a target=xrefwindow id=d41976e3583 href="http://meetinglibrary.asco.org/content/166012-176">Reference Source</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d41976e3592 class=n-a></a>Kumar S, Vij R, Kaufman JL, <i> et al.</i>: Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma. <i>J Clin Oncol.</i> 2016; <b>34</b>(suppl): abstract 8032. <a target=xrefwindow id=d41976e3603 href="http://meetinglibrary.asco.org/content/163810-176">Reference Source</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d41976e3613 class=n-a></a>Moreau P, Chanan-Khan AAA, Roberts AW, <i> et al.</i>: Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. <i>J Clin Oncol.</i> 2016; <b>34</b>(suppl): abstract 8011. <a target=xrefwindow id=d41976e3624 href="http://meetinglibrary.asco.org/content/163816-176">Reference Source</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d41976e3633 class=n-a></a>Pan R, Hogdal LJ, Benito JM, <i> et al.</i>: Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. <i>Cancer Discov.</i> 2014; <b>4</b>(3): 362–75. <a target=xrefwindow id=d41976e3644 href="http://www.ncbi.nlm.nih.gov/pubmed/24346116">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3647 href="http://dx.doi.org/10.1158/2159-8290.CD-13-0609">Publisher Full Text </a> | <a target=xrefwindow id=d41976e3651 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3975047">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726638619"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3660 class=n-a></a>Konopleva M, Pollyea DA, Potluri J, <i> et al.</i>: Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. <i>Cancer Discov.</i> 2016; <b>6</b>(10): 1106–17. <a target=xrefwindow id=d41976e3671 href="http://www.ncbi.nlm.nih.gov/pubmed/27520294">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3674 href="http://dx.doi.org/10.1158/2159-8290.CD-16-0313">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726638619">F1000 Recommendation</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d41976e3687 class=n-a></a>Kaufmann SH, Karp JE, Svingen PA, <i> et al.</i>: Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. <i>Blood.</i> 1998; <b>91</b>(3): 991–1000. <a target=xrefwindow id=d41976e3698 href="http://www.ncbi.nlm.nih.gov/pubmed/9446661">PubMed Abstract </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726620288"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3707 class=n-a></a>Kontro M, Kumar A, Majumder MM, <i> et al.</i>: HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. <i>Leukemia.</i> 2016. <a target=xrefwindow id=d41976e3715 href="http://www.ncbi.nlm.nih.gov/pubmed/27499136">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3718 href="http://dx.doi.org/10.1038/leu.2016.222">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726620288">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d41976e3731 class=n-a></a>Lin TL, Strickland SA, Fiedler W, <i> et al.</i>: Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥ 65 with acute myelogenous leukemia. <i>J Clin Oncol.</i> 2016; <b>34</b>(suppl): abstract 7007. <a target=xrefwindow id=d41976e3742 href="http://meetinglibrary.asco.org/content/165093-176">Reference Source</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d41976e3752 class=n-a></a>Pollyea DA, Dinardo CD, Thirman MJ, <i> et al.</i>: Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥ 65 years ineligible for standard induction therapy. <i>J Clin Oncol.</i> 2015; <b>34</b>(Suppl): (suppl., abstract 7009). <a target=xrefwindow id=d41976e3763 href="http://meetinglibrary.asco.org/content/168695-176">Reference Source</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/2381956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3772 class=n-a></a>Beroukhim R, Mermel CH, Porter D, <i> et al.</i>: The landscape of somatic copy-number alteration across human cancers. <i>Nature.</i> 2010; <b>463</b>(7283): 899–905. <a target=xrefwindow id=d41976e3783 href="http://www.ncbi.nlm.nih.gov/pubmed/20164920">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3786 href="http://dx.doi.org/10.1038/nature08822">Publisher Full Text </a> | <a target=xrefwindow id=d41976e3790 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2826709">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/2381956">F1000 Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d41976e3803 class=n-a></a>Jiang SX, Sato Y, Kuwao S, <i> et al.</i>: Expression of <i>bcl</i>-2 oncogene protein is prevalent in small cell lung carcinomas. <i>J Pathol.</i> 1995; <b>177</b>(2): 135–8. <a target=xrefwindow id=d41976e3817 href="http://www.ncbi.nlm.nih.gov/pubmed/7490679">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3821 href="http://dx.doi.org/10.1002/path.1711770206">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d41976e3830 class=n-a></a>Vaillant F, Merino D, Lee L, <i> et al.</i>: Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. <i>Cancer Cell.</i> 2013; <b>24</b>(1): 120–9. <a target=xrefwindow id=d41976e3841 href="http://www.ncbi.nlm.nih.gov/pubmed/23845444">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3844 href="http://dx.doi.org/10.1016/j.ccr.2013.06.002">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d41976e3853 class=n-a></a>Zhang H, Xue J, Hessler P, <i> et al.</i>: Genomic analysis and selective small molecule inhibition identifies BCL-X<sub>L</sub> as a critical survival factor in a subset of colorectal cancer. <i>Mol Cancer.</i> 2015; <b>14</b>: 126. <a target=xrefwindow id=d41976e3867 href="http://www.ncbi.nlm.nih.gov/pubmed/26134786">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3871 href="http://dx.doi.org/10.1186/s12943-015-0397-y">Publisher Full Text </a> | <a target=xrefwindow id=d41976e3874 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4487849">Free Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d41976e3883 class=n-a></a>Castilla C, Congregado B, Chinchón D, <i> et al.</i>: Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. <i>Endocrinology.</i> 2006; <b>147</b>(10): 4960–7. <a target=xrefwindow id=d41976e3894 href="http://www.ncbi.nlm.nih.gov/pubmed/16794010">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3897 href="http://dx.doi.org/10.1210/en.2006-0502">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725259936"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3907 class=n-a></a>Keitel U, Scheel A, Thomale J, <i> et al.</i>: Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation. <i>Oncotarget.</i> 2014; <b>5</b>(23): 11778–91. <a target=xrefwindow id=d41976e3918 href="http://www.ncbi.nlm.nih.gov/pubmed/25473892">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3921 href="http://dx.doi.org/10.18632/oncotarget.2634">Publisher Full Text </a> | <a target=xrefwindow id=d41976e3925 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4322974">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725259936">F1000 Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d41976e3938 class=n-a></a>Amundson SA, Myers TG, Scudiero D, <i> et al.</i>: An informatics approach identifying markers of chemosensitivity in human cancer cell lines. <i>Cancer Res.</i> 2000; <b>60</b>(21): 6101–10. <a target=xrefwindow id=d41976e3949 href="http://www.ncbi.nlm.nih.gov/pubmed/11085534">PubMed Abstract </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d41976e3958 class=n-a></a>Lessene G, Czabotar PE, Sleebs BE, <i> et al.</i>: Structure-guided design of a selective BCL-X<sub>L</sub> inhibitor. <i>Nat Chem Biol.</i> 2013; <b>9</b>(6): 390–7. <a target=xrefwindow id=d41976e3972 href="http://www.ncbi.nlm.nih.gov/pubmed/23603658">PubMed Abstract </a> | <a target=xrefwindow id=d41976e3976 href="http://dx.doi.org/10.1038/nchembio.1246">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/722006164"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e3985 class=n-a></a>Tao ZF, Hasvold L, Wang L, <i> et al.</i>: Discovery of a Potent and Selective BCL-X<sub>L</sub> Inhibitor with <i>in Vivo</i> Activity. <i>ACS Med Chem Lett.</i> 2014; <b>5</b>(10): 1088–93. <a target=xrefwindow id=d41976e4003 href="http://www.ncbi.nlm.nih.gov/pubmed/25313317">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4006 href="http://dx.doi.org/10.1021/ml5001867">Publisher Full Text </a> | <a target=xrefwindow id=d41976e4009 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4190639">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/722006164">F1000 Recommendation</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726290880"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e4022 class=n-a></a>Abed MN, Abdullah MI, Richardson A: Antagonism of Bcl-X<sub>L</sub> is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. <i>J Ovarian Res.</i> 2016; <b>9</b>: 25. <a target=xrefwindow id=d41976e4033 href="http://www.ncbi.nlm.nih.gov/pubmed/27080533">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4036 href="http://dx.doi.org/10.1186/s13048-016-0234-y">Publisher Full Text </a> | <a target=xrefwindow id=d41976e4040 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4832520">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726290880">F1000 Recommendation</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725818536"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e4053 class=n-a></a>Baranski Z, de Jong Y, Ilkova T, <i> et al.</i>: Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin. <i>Oncotarget.</i> 2015; <b>6</b>(34): 36113–25. <a target=xrefwindow id=d41976e4064 href="http://www.ncbi.nlm.nih.gov/pubmed/26416351">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4067 href="http://dx.doi.org/10.18632/oncotarget.5333">Publisher Full Text </a> | <a target=xrefwindow id=d41976e4071 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4742165">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725818536">F1000 Recommendation</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d41976e4085 class=n-a></a>Hussain SR , Cheney CM, Johnson AJ, <i> et al.</i>: Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. <i>Clin Cancer Res.</i> 2007; <b>13</b>(7): 2144–50. <a target=xrefwindow id=d41976e4096 href="http://www.ncbi.nlm.nih.gov/pubmed/17404098">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4099 href="http://dx.doi.org/10.1158/1078-0432.CCR-06-2294">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d41976e4108 class=n-a></a>Kitada S, Andersen J, Akar S, <i> et al.</i>: Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with <i>In vitro</i> and <i>In vivo</i> chemoresponses. <i>Blood.</i> 1998; <b>91</b>(9): 3379–89. <a target=xrefwindow id=d41976e4126 href="http://www.ncbi.nlm.nih.gov/pubmed/9558396">PubMed Abstract </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d41976e4135 class=n-a></a>Backus HH, van Riel JM, van Groeningen CJ, <i> et al.</i>: Rb, <i>mcl-1</i> and <i>p53</i> expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. <i>Ann Oncol.</i> 2001; <b>12</b>(6): 779–85. <a target=xrefwindow id=d41976e4153 href="http://www.ncbi.nlm.nih.gov/pubmed/11484952">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4156 href="http://dx.doi.org/10.1023/A:1011112227044">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d41976e4165 class=n-a></a>Shigemasa K, Katoh O, Shiroyama Y, <i> et al.</i>: Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas. <i>Jpn J Cancer Res.</i> 2002; <b>93</b>(5): 542–50. <a target=xrefwindow id=d41976e4176 href="http://www.ncbi.nlm.nih.gov/pubmed/12036450">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4179 href="http://dx.doi.org/10.1111/j.1349-7006.2002.tb01289.x">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d41976e4188 class=n-a></a>Wuillème-Toumi S, Robillard N, Gomez P, <i> et al.</i>: Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. <i>Leukemia.</i> 2005; <b>19</b>(7): 1248–52. <a target=xrefwindow id=d41976e4199 href="http://www.ncbi.nlm.nih.gov/pubmed/15902294">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4202 href="http://dx.doi.org/10.1038/sj.leu.2403784">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d41976e4211 class=n-a></a>Sieghart W, Losert D, Strommer S, <i> et al.</i>: Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. <i>J Hepatol.</i> 2006; <b>44</b>(1): 151–7. <a target=xrefwindow id=d41976e4222 href="http://www.ncbi.nlm.nih.gov/pubmed/16289418">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4225 href="http://dx.doi.org/10.1016/j.jhep.2005.09.010">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d41976e4235 class=n-a></a>Zhuang L, Lee CS, Scolyer RA, <i> et al.</i>: Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. <i>Mod Pathol.</i> 2007; <b>20</b>(4): 416–26. <a target=xrefwindow id=d41976e4246 href="http://www.ncbi.nlm.nih.gov/pubmed/17384650">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4249 href="http://dx.doi.org/10.1038/modpathol.3800750">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d41976e4258 class=n-a></a>Ding Q, He X, Xia W, <i> et al.</i>: Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. <i>Cancer Res.</i> 2007; <b>67</b>(10): 4564–71. <a target=xrefwindow id=d41976e4269 href="http://www.ncbi.nlm.nih.gov/pubmed/17495324">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4272 href="http://dx.doi.org/10.1158/0008-5472.CAN-06-1788">Publisher Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d41976e4281 class=n-a></a>Quinn BA, Dash R, Azab B, <i> et al.</i>: Targeting Mcl-1 for the therapy of cancer. <i>Expert Opin Investig Drugs.</i> 2011; <b>20</b>(10): 1397–411. <a target=xrefwindow id=d41976e4292 href="http://www.ncbi.nlm.nih.gov/pubmed/21851287">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4295 href="http://dx.doi.org/10.1517/13543784.2011.609167">Publisher Full Text </a> | <a target=xrefwindow id=d41976e4299 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3205956">Free Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d41976e4308 class=n-a></a>Meng XW, Lee SH, Dai H, <i> et al.</i>: Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. <i>J Biol Chem.</i> 2007; <b>282</b>(41): 29831–46. <a target=xrefwindow id=d41976e4319 href="http://www.ncbi.nlm.nih.gov/pubmed/17698840">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4322 href="http://dx.doi.org/10.1074/jbc.M706110200">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d41976e4331 class=n-a></a>Konopleva M, Contractor R, Tsao T, <i> et al.</i>: Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. <i>Cancer Cell.</i> 2006; <b>10</b>(5): 375–88. <a target=xrefwindow id=d41976e4342 href="http://www.ncbi.nlm.nih.gov/pubmed/17097560">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4345 href="http://dx.doi.org/10.1016/j.ccr.2006.10.006">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d41976e4354 class=n-a></a>Chen S, Dai Y, Harada H, <i> et al.</i>: Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. <i>Cancer Res.</i> 2007; <b>67</b>(2): 782–91. <a target=xrefwindow id=d41976e4365 href="http://www.ncbi.nlm.nih.gov/pubmed/17234790">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4368 href="http://dx.doi.org/10.1158/0008-5472.CAN-06-3964">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725314829"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e4378 class=n-a></a>Leverson JD, Zhang H, Chen J, <i> et al.</i>: Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). <i>Cell Death Dis.</i> 2015; <b>6</b>: e1590. <a target=xrefwindow id=d41976e4389 href="http://www.ncbi.nlm.nih.gov/pubmed/25590800">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4392 href="http://dx.doi.org/10.1038/cddis.2014.561">Publisher Full Text </a> | <a target=xrefwindow id=d41976e4396 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4669759">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725314829">F1000 Recommendation</a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d41976e4409 class=n-a></a>Yecies D, Carlson NE, Deng J, <i> et al.</i>: Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. <i>Blood.</i> 2010; <b>115</b>(16): 3304–13. <a target=xrefwindow id=d41976e4420 href="http://www.ncbi.nlm.nih.gov/pubmed/20197552">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4423 href="http://dx.doi.org/10.1182/blood-2009-07-233304">Publisher Full Text </a> | <a target=xrefwindow id=d41976e4427 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2858493">Free Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725518097"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e4436 class=n-a></a>Xiao Y, Nimmer P, Sheppard GS, <i> et al.</i>: MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor. <i>Mol Cancer Ther.</i> 2015; <b>14</b>(8): 1837–47. <a target=xrefwindow id=d41976e4447 href="http://www.ncbi.nlm.nih.gov/pubmed/26013319">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4450 href="http://dx.doi.org/10.1158/1535-7163.MCT-14-0928">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725518097">F1000 Recommendation</a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d41976e4463 class=n-a></a>Al-Harbi S, Hill BT, Mazumder S, <i> et al.</i>: An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. <i>Blood.</i> 2011; <b>118</b>(13): 3579–90. <a target=xrefwindow id=d41976e4474 href="http://www.ncbi.nlm.nih.gov/pubmed/21772052">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4477 href="http://dx.doi.org/10.1182/blood-2011-03-340364">Publisher Full Text </a> | <a target=xrefwindow id=d41976e4481 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3186334">Free Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/715898100"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e4490 class=n-a></a>Perciavalle RM, Stewart DP, Koss B, <i> et al.</i>: Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. <i>Nat Cell Biol.</i> 2012; <b>14</b>(6): 575–83. <a target=xrefwindow id=d41976e4501 href="http://www.ncbi.nlm.nih.gov/pubmed/22544066">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4504 href="http://dx.doi.org/10.1038/ncb2488">Publisher Full Text </a> | <a target=xrefwindow id=d41976e4508 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3401947">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/715898100">F1000 Recommendation</a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d41976e4521 class=n-a></a>Mérino D, Khaw SL, Glaser SP, <i> et al.</i>: Bcl-2, Bcl-x<sub>L</sub>, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. <i>Blood.</i> 2012; <b>119</b>(24): 5807–16. <a target=xrefwindow id=d41976e4535 href="http://www.ncbi.nlm.nih.gov/pubmed/22538851">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4539 href="http://dx.doi.org/10.1182/blood-2011-12-400929">Publisher Full Text </a> | <a target=xrefwindow id=d41976e4542 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3382939">Free Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718232311"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e4552 class=n-a></a>Khaw SL, Mérino D, Anderson MA, <i> et al.</i>: Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. <i>Leukemia.</i> 2014; <b>28</b>(6): 1207–15. <a target=xrefwindow id=d41976e4563 href="http://www.ncbi.nlm.nih.gov/pubmed/24402163">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4566 href="http://dx.doi.org/10.1038/leu.2014.1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718232311">F1000 Recommendation</a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1980957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e4579 class=n-a></a>Schwickart M, Huang X, Lill JR, <i> et al.</i>: Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. <i>Nature.</i> 2010; <b>463</b>(7277): 103–7. <a target=xrefwindow id=d41976e4590 href="http://www.ncbi.nlm.nih.gov/pubmed/20023629">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4593 href="http://dx.doi.org/10.1038/nature08646">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1980957">F1000 Recommendation</a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/9173956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e4606 class=n-a></a>Wertz IE, Kusam S, Lam C, <i> et al.</i>: Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. <i>Nature.</i> 2011; <b>471</b>(7336): 110–4. <a target=xrefwindow id=d41976e4617 href="http://www.ncbi.nlm.nih.gov/pubmed/21368834">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4620 href="http://dx.doi.org/10.1038/nature09779">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/9173956">F1000 Recommendation</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d41976e4633 class=n-a></a>Deng J, Carlson N, Takeyama K, <i> et al.</i>: BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. <i>Cancer Cell.</i> 2007; <b>12</b>(2): 171–85. <a target=xrefwindow id=d41976e4644 href="http://www.ncbi.nlm.nih.gov/pubmed/17692808">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4647 href="http://dx.doi.org/10.1016/j.ccr.2007.07.001">Publisher Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/4698956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e4656 class=n-a></a>Ryan JA, Brunelle JK, Letai A: Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4<sup>+</sup> CD8<sup>+</sup> thymocytes. <i>Proc Natl Acad Sci U S A.</i> 2010; <b>107</b>(29): 12895–900. <a target=xrefwindow id=d41976e4670 href="http://www.ncbi.nlm.nih.gov/pubmed/20615979">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4674 href="http://dx.doi.org/10.1073/pnas.0914878107">Publisher Full Text </a> | <a target=xrefwindow id=d41976e4677 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2919900">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/4698956">F1000 Recommendation</a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d41976e4690 class=n-a></a>Ni Chonghaile T, Sarosiek KA, Vo TT, <i> et al.</i>: Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. <i>Science.</i> 2011; <b>334</b>(6059): 1129–33. <a target=xrefwindow id=d41976e4701 href="http://www.ncbi.nlm.nih.gov/pubmed/22033517">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4704 href="http://dx.doi.org/10.1126/science.1206727">Publisher Full Text </a> | <a target=xrefwindow id=d41976e4708 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3280949">Free Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717967902"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e4718 class=n-a></a>Vo TT, Ryan J, Carrasco R, <i> et al.</i>: Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. <i>Cell.</i> 2012; <b>151</b>(2): 344–55. <a target=xrefwindow id=d41976e4729 href="http://www.ncbi.nlm.nih.gov/pubmed/23063124">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4732 href="http://dx.doi.org/10.1016/j.cell.2012.08.038">Publisher Full Text </a> | <a target=xrefwindow id=d41976e4736 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3534747">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717967902">F1000 Recommendation</a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1024421"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e4749 class=n-a></a>Chen L, Willis SN, Wei A, <i> et al.</i>: Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. <i>Mol Cell.</i> 2005; <b>17</b>(3): 393–403. <a target=xrefwindow id=d41976e4760 href="http://www.ncbi.nlm.nih.gov/pubmed/15694340">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4763 href="http://dx.doi.org/10.1016/j.molcel.2004.12.030">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1024421">F1000 Recommendation</a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718479856"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e4776 class=n-a></a>Chonghaile TN, Roderick JE, Glenfield C, <i> et al.</i>: Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. <i>Cancer Discov.</i> 2014; <b>4</b>(9): 1074–87. <a target=xrefwindow id=d41976e4787 href="http://www.ncbi.nlm.nih.gov/pubmed/24994123">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4790 href="http://dx.doi.org/10.1158/2159-8290.CD-14-0353">Publisher Full Text </a> | <a target=xrefwindow id=d41976e4794 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4154982">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718479856">F1000 Recommendation</a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725369660"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e4807 class=n-a></a>Montero J, Sarosiek KA, DeAngelo JD, <i> et al.</i>: Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. <i>Cell.</i> 2015; <b>160</b>(5): 977–89. <a target=xrefwindow id=d41976e4818 href="http://www.ncbi.nlm.nih.gov/pubmed/25723171">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4821 href="http://dx.doi.org/10.1016/j.cell.2015.01.042">Publisher Full Text </a> | <a target=xrefwindow id=d41976e4825 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4391197">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725369660">F1000 Recommendation</a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d41976e4838 class=n-a></a>Dai H, Meng XW, Lee SH, <i> et al.</i>: Context-dependent Bcl-2/Bak interactions regulate lymphoid cell apoptosis. <i>J Biol Chem.</i> 2009; <b>284</b>(27): 18311–22. <a target=xrefwindow id=d41976e4849 href="http://www.ncbi.nlm.nih.gov/pubmed/19351886">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4852 href="http://dx.doi.org/10.1074/jbc.M109.004770">Publisher Full Text </a> | <a target=xrefwindow id=d41976e4856 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2709361">Free Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d41976e4865 class=n-a></a>Smith AJ, Dai H, Correia C, <i> et al.</i>: Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. <i>J Biol Chem.</i> 2011; <b>286</b>(20): 17682–92. <a target=xrefwindow id=d41976e4876 href="http://www.ncbi.nlm.nih.gov/pubmed/21454712">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4879 href="http://dx.doi.org/10.1074/jbc.M110.189092">Publisher Full Text </a> | <a target=xrefwindow id=d41976e4883 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3093844">Free Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d41976e4893 class=n-a></a>Krajewski S, Tanaka S, Takayama S, <i> et al.</i>: Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. <i>Cancer Res.</i> 1993; <b>53</b>(19): 4701–14. <a target=xrefwindow id=d41976e4904 href="http://www.ncbi.nlm.nih.gov/pubmed/8402648">PubMed Abstract </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d41976e4913 class=n-a></a>Krajewski S, Bodrug S, Gascoyne R, <i> et al.</i>: Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. <i>Am J Pathol.</i> 1994; <b>145</b>(3): 515–25. <a target=xrefwindow id=d41976e4924 href="http://www.ncbi.nlm.nih.gov/pubmed/8080035">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4927 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1890333">Free Full Text </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1024143"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e4936 class=n-a></a>Opferman JT, Iwasaki H, Ong CC, <i> et al.</i>: Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. <i>Science.</i> 2005; <b>307</b>(5712): 1101–4. <a target=xrefwindow id=d41976e4947 href="http://www.ncbi.nlm.nih.gov/pubmed/15718471">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4950 href="http://dx.doi.org/10.1126/science.1106114">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1024143">F1000 Recommendation</a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726273117"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d41976e4963 class=n-a></a>O'Neill KL, Huang K, Zhang J, <i> et al.</i>: Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane. <i>Genes Dev.</i> 2016; <b>30</b>(8): 973–88. <a target=xrefwindow id=d41976e4974 href="http://www.ncbi.nlm.nih.gov/pubmed/27056669">PubMed Abstract </a> | <a target=xrefwindow id=d41976e4977 href="http://dx.doi.org/10.1101/gad.276725.115">Publisher Full Text </a> | <a target=xrefwindow id=d41976e4981 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4840302">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726273117">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 01 Dec 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2804.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2804.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Division of Oncology Research , Mayo Clinic, Rochester, MN, 55905, USA<br/> <sup>2</sup> Department of Molecular Pharmacology &amp; Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA<br/> <sup>3</sup> Center for Medical Physics and Technology, Hefei Institute of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/5-2804/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 01 Dec 2016, 5:2804 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.9629.1">https://doi.org/10.12688/f1000research.9629.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2016 Dai H <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=10375 data-id=9629 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9629.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/5-2804/v1/pdf?article_uuid=bdd0363f-6d1e-467e-85a9-b9f68b3f55ab" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.9629.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Dai H, Meng XW and Kaufmann SH. Mitochondrial apoptosis and BH3 mimetics [version 1; peer review: 3 approved] <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2804 (<a href="https://doi.org/10.12688/f1000research.9629.1" target=_blank>https://doi.org/10.12688/f1000research.9629.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=9629 id=mobile-track-article-signin-9629 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9629?target=/articles/5-2804.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10375 /> <input name=articleId type=hidden value=9629 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Sharad Kumar</strong>, Centre for Cancer Biology, University of South Australia, Australia </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Alan Richardson</strong>, Keele University, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Kapil Bhalla</strong>, Department of Leukemia, M.D. Anderson Cancer Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 01 Dec 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2804.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2804.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=18257-17747></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=18259-17748></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=18258-17749></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/5-2804/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>01 Dec 16</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Sharad Kumar</strong>, Centre for Cancer Biology, University of South Australia, Australia </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Alan Richardson</strong>, Keele University, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Kapil Bhalla</strong>, Department of Leukemia, M.D. Anderson Cancer Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/5-2804.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/5-2804/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Mitochondrial apoptosis and BH3 mimetics".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/5-2804/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/5-2804/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/5-2804/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Dai H et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/5-2804/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/5-2804",
            templates : {
                twitter : "Mitochondrial apoptosis and BH3 mimetics. Dai H et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/5-2804/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Mitochondrial apoptosis and BH3 mimetics", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Mitochondrial apoptosis and BH3 mimetics", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/9629/10375")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "10375");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "17747": 0,
                           "17748": 0,
                           "17749": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "3c87d64a-87ba-41d3-af6f-df0de0c6d159";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2804.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2804.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2804.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/5-2804.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/5-2804.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>